2f:I[703058,["/_next/static/immutable/chunks/3bhq_5eh1d760.js","/_next/static/immutable/chunks/1855-ogyi8eh4.js","/_next/static/immutable/chunks/2pfsjpn6k6zlg.js","/_next/static/immutable/chunks/26c7v3_3uwnwu.js","/_next/static/immutable/chunks/25a3ozcrvi1ff.js","/_next/static/immutable/chunks/2r4wx50nvjh_4.js","/_next/static/immutable/chunks/23fsw06hsi5b1.js","/_next/static/immutable/chunks/06_yt270h41rg.js","/_next/static/immutable/chunks/3ezsiz-7shkna.js","/_next/static/immutable/chunks/20x2y96ldu5wx.js","/_next/static/immutable/chunks/2lxntcm3pd1_h.js","/_next/static/immutable/chunks/00dgco8irq3jw.js","/_next/static/immutable/chunks/00nwe-kq0rboc.js","/_next/static/immutable/chunks/2051ffx3xzio9.js"],"PaperListPageClient"] 30:T48e,A total of 19 907 patients (mean [SD] age, 20.6 [7.8] years; 10 504 females [52.8%]) were included, among whom 4482 (22.5%) had acne relapse and 1639 (8.2%) had isotretinoin retrial. Female sex (hazard ratio [HR], 1.43; 95% CI, 1.35-1.52) was significantly associated with increased rates of acne relapse, and isotretinoin cumulative dosage (mg/kg) was associated with a decreased rate of acne relapse (HR, 0.996; 95% CI, 0.995-0.997). Furthermore, daily dose was not associated with decreased risk of acne relapse or isotretinoin retrial among those with conventional and high cumulative dosages. Female sex (HR, 0.68; 95% CI, 0.62-0.76) and isotretinoin cumulative dosage (HR, 0.99; 95% CI, 0.98-0.99) were associated with decreased rates of isotretinoin retrial. Stratification by cumulative dosage indicated that higher cumulative dosage was associated with decreased rates of retrial among patients with low (<120 mg/kg) and conventional (120-220 mg/kg), but not high (>220 mg/kg) cumulative dosage. Maximum daily dose (mg/kg/d) was not negatively associated with acne relapse or isotretinoin retrial in patients with cumulative dosage of 120 mg/kg or more.31:T9da,Isotretinoin is the only medical acne treatment capable of inducing acne remission; however, some patients experience acne relapse and require retrials of isotretinoin. There is a need to understand who is most at risk and how daily dose and cumulative dosage can influence outcomes. To assess rates of acne relapse and isotretinoin retrial and to identify associated factors among patients with acne who received an isotretinoin treatment course. This cohort study used data from the MarketScan commercial claims database from January 1, 2017, to December 31, 2020, to identify patients with acne who were 12 years or older and had received isotretinoin for 4 months or longer, with at least 1 year of continuous enrollment after completion of isotretinoin. Data analyses were performed from June 30, 2024, to August 1, 2024. Multivariable Cox proportional hazards regression was used to quantify associations of patient demographic and treatment characteristics with acne relapse and isotretinoin retrial. A total of 19 907 patients (mean [SD] age, 20.6 [7.8] years; 10 504 females [52.8%]) were included, among whom 4482 (22.5%) had acne relapse and 1639 (8.2%) had isotretinoin retrial. Female sex (hazard ratio [HR], 1.43; 95% CI, 1.35-1.52) was significantly associated with increased rates of acne relapse, and isotretinoin cumulative dosage (mg/kg) was associated with a decreased rate of acne relapse (HR, 0.996; 95% CI, 0.995-0.997). Furthermore, daily dose was not associated with decreased risk of acne relapse or isotretinoin retrial among those with conventional and high cumulative dosages. Female sex (HR, 0.68; 95% CI, 0.62-0.76) and isotretinoin cumulative dosage (HR, 0.99; 95% CI, 0.98-0.99) were associated with decreased rates of isotretinoin retrial. Stratification by cumulative dosage indicated that higher cumulative dosage was associated with decreased rates of retrial among patients with low (<120 mg/kg) and conventional (120-220 mg/kg), but not high (>220 mg/kg) cumulative dosage. Maximum daily dose (mg/kg/d) was not negatively associated with acne relapse or isotretinoin retrial in patients with cumulative dosage of 120 mg/kg or more. The findings of this cohort study suggest that higher cumulative dosage may potentially reduce risk of acne relapse and isotretinoin retrial. Furthermore, daily dose was not associated with decreased risk of the outcomes for conventional and high cumulative dosage; therefore, daily dosing could be individualized to patient goals and preferences.32:Tc4b,ImportanceIsotretinoin is the only medical acne treatment capable of inducing acne remission; however, some patients experience acne relapse and require retrials of isotretinoin. There is a need to understand who is most at risk and how daily dose and cumulative dosage can influence outcomes.ObjectiveTo assess rates of acne relapse and isotretinoin retrial and to identify associated factors among patients with acne who received an isotretinoin treatment course.Design, Setting, and ParticipantsThis cohort study used data from the MarketScan commercial claims database from January 1, 2017, to December 31, 2020, to identify patients with acne who were 12 years or older and had received isotretinoin for 4 months or longer, with at least 1 year of continuous enrollment after completion of isotretinoin. Data analyses were performed from June 30, 2024, to August 1, 2024.Main Outcomes and MeasuresMultivariable Cox proportional hazards regression was used to quantify associations of patient demographic and treatment characteristics with acne relapse and isotretinoin retrial.ResultsA total of 19 907 patients (mean [SD] age, 20.6 [7.8] years; 10 504 females [52.8%]) were included, among whom 4482 (22.5%) had acne relapse and 1639 (8.2%) had isotretinoin retrial. Female sex (hazard ratio [HR], 1.43; 95% CI, 1.35-1.52) was significantly associated with increased rates of acne relapse, and isotretinoin cumulative dosage (mg/kg) was associated with a decreased rate of acne relapse (HR, 0.996; 95% CI, 0.995-0.997). Furthermore, daily dose was not associated with decreased risk of acne relapse or isotretinoin retrial among those with conventional and high cumulative dosages. Female sex (HR, 0.68; 95% CI, 0.62-0.76) and isotretinoin cumulative dosage (HR, 0.99; 95% CI, 0.98-0.99) were associated with decreased rates of isotretinoin retrial. Stratification by cumulative dosage indicated that higher cumulative dosage was associated with decreased rates of retrial among patients with low (&lt;120 mg/kg) and conventional (120-220 mg/kg), but not high (&gt;220 mg/kg) cumulative dosage. Maximum daily dose (mg/kg/d) was not negatively associated with acne relapse or isotretinoin retrial in patients with cumulative dosage of 120 mg/kg or more.Conclusions and RelevanceThe findings of this cohort study suggest that higher cumulative dosage may potentially reduce risk of acne relapse and isotretinoin retrial. Furthermore, daily dose was not associated with decreased risk of the outcomes for conventional and high cumulative dosage; therefore, daily dosing could be individualized to patient goals and preferences.33:T593,Acne vulgaris commonly affects adults, adolescents, and preadolescents aged 9 years or older. The objective of this study was to provide evidence-based recommendations for the management of acne. A work group conducted a systematic review and applied the Grading of Recommendations, Assessment, Development, and Evaluation approach for assessing the certainty of evidence and formulating and grading recommendations. This guideline presents 18 evidence-based recommendations and 5 good practice statements. Strong recommendations are made for benzoyl peroxide, topical retinoids, topical antibiotics, and oral doxycycline. Oral isotretinoin is strongly recommended for acne that is severe, causing psychosocial burden or scarring, or failing standard oral or topical therapy. Conditional recommendations are made for topical clascoterone, salicylic acid, and azelaic acid, as well as for oral minocycline, sarecycline, combined oral contraceptive pills, and spironolactone. Combining topical therapies with multiple mechanisms of action, limiting systemic antibiotic use, combining systemic antibiotics with topical therapies, and adding intralesional corticosteroid injections for larger acne lesions are recommended as good practice statements. Analysis is based on the best available evidence at the time of the systematic review. These guidelines provide evidence-based recommendations for the management of acne vulgaris.25:[[["$","script","0",{"type":"application/ld+json","dangerouslySetInnerHTML":{"__html":"{\"@context\":\"https://schema.org\",\"@type\":\"CollectionPage\",\"name\":\"Oral Retinoid: modality Research & Clinical Takeaways\",\"description\":\"Explore peer-reviewed papers on Oral Retinoid (modality). Clinician-written summaries and actionable practice insights. Updated daily.\",\"url\":\"https://www.reachrx.ai/hub/tag/modality/Oral%20Retinoid\",\"breadcrumb\":{\"@type\":\"BreadcrumbList\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https://www.reachrx.ai\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Research Hub\",\"item\":\"https://www.reachrx.ai/hub\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Modalities\",\"item\":\"https://www.reachrx.ai/hub/tag/modality\"},{\"@type\":\"ListItem\",\"position\":4,\"name\":\"Oral Retinoid\",\"item\":\"https://www.reachrx.ai/hub/tag/modality/Oral%20Retinoid\"}]}}"}}]],["$","$L2f",null,{"title":"Oral Retinoid: Research & Clinical Takeaways","description":"Review evidence by treatment modality: Oral Retinoid — concise summaries and practical next steps.","papers":[{"doi":"10.1001/jamadermatol.2024.5416","pmid":"39813053","title":"Acne Relapse and Isotretinoin Retrial in Patients With Acne","journal_title":"JAMA Dermatology","journal_issn":"2168-6068","published_at":"2025-01-15T00:00:00.000Z","url":"https://doi.org/10.1001/jamadermatol.2024.5416","source_score":64,"is_retracted":false,"is_open_access":false,"raw_metadata":{"ooir":{"day":"2025-01-22","doi":"10.1001/jamadermatol.2024.5416","days":"30","issn":"2168-6068","rank":"4","field":"Clinical Medicine","score":"64","category":"Dermatology","categories":["Dermatology"],"_categories":["Dermatology"]},"pubmed":{"doi":"10.1001/jamadermatol.2024.5416","title":"Acne Relapse and Isotretinoin Retrial in Patients With Acne.","journal":"JAMA dermatology","methods":"","results":"$30","abstract":"$31","keywords":[],"pubmed_id":"39813053","conclusions":"","publication_date":"2025-01-15T00:00:00"},"crossref":{"DOI":"10.1001/jamadermatol.2024.5416","URL":"https://doi.org/10.1001/jamadermatol.2024.5416","ISSN":["2168-6068"],"link":[{"URL":"https://jamanetwork.com/journals/jamadermatology/articlepdf/2829255/jamadermatology_lai_2025_oi_240066_1744811605.49753.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"page":"367","type":"journal-article","issue":"4","score":1,"title":["Acne Relapse and Isotretinoin Retrial in Patients With Acne"],"author":[{"given":"Jenny","family":"Lai","sequence":"first","affiliation":[{"name":"Harvard Medical School, Boston, Massachusetts"},{"name":"Department of Dermatology, Brigham and Women’s Hospital, Boston, Massachusetts"}]},{"given":"John S.","family":"Barbieri","sequence":"additional","affiliation":[{"name":"Harvard Medical School, Boston, Massachusetts"},{"name":"Department of Dermatology, Brigham and Women’s Hospital, Boston, Massachusetts"},{"name":"Associate Editor and Evidence-based Practice Editor, JAMA Dermatology"}]}],"issued":{"date-parts":[[2025,4,1]]},"member":"10","prefix":"10.1001","source":"Crossref","volume":"161","created":{"date-time":"2025-01-15T16:00:43Z","timestamp":1736956843000,"date-parts":[[2025,1,15]]},"indexed":{"date-time":"2025-04-17T04:11:40Z","timestamp":1744863100932,"date-parts":[[2025,4,17]]},"subject":[],"abstract":"$32","language":"en","relation":{},"resource":{"primary":{"URL":"https://jamanetwork.com/journals/jamadermatology/fullarticle/2829255"}},"subtitle":[],"deposited":{"date-time":"2025-04-16T15:01:06Z","timestamp":1744815666000,"date-parts":[[2025,4,16]]},"issn-type":[{"type":"print","value":"2168-6068"}],"published":{"date-parts":[[2025,4,1]]},"publisher":"American Medical Association (AMA)","reference":[{"DOI":"10.1016/j.jaad.2023.12.017","key":"doi240066r1","year":"2024","issue":"5","author":"Reynolds","volume":"90","first-page":"1006.e1","unstructured":null,"article-title":"Guidelines of care for the management of acne vulgaris.","journal-title":"J Am Acad Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1111/j.1440-0960.2010.00657.x","key":"doi240066r2","year":"2010","issue":"4","author":"Rademaker","volume":"51","first-page":"248","unstructured":null,"article-title":"Adverse effects of isotretinoin: a retrospective review of 1743 patients started on isotretinoin.","journal-title":"Australas J Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1111/j.1365-2133.1984.tb04030.x","key":"doi240066r3","year":"1984","issue":"1","author":"Jones","volume":"111","first-page":"123","unstructured":null,"article-title":"Remission rates in acne patients treated with various doses of 13-cis-retinoic acid (isotretinoin).","journal-title":"Br J Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1111/j.1365-2133.1993.tb11850.x","key":"doi240066r4","year":"1993","issue":"3","author":"Stainforth","volume":"129","first-page":"297","unstructured":null,"article-title":"Isotretinoin for the treatment of acne vulgaris: which factors may predict the need for more than one course?","journal-title":"Br J Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1111/j.1365-2133.1993.tb11849.x","key":"doi240066r5","year":"1993","issue":"3","author":"Layton","volume":"129","first-page":"292","unstructured":null,"article-title":"Isotretinoin for acne vulgaris–10 years later: a safe and successful treatment.","journal-title":"Br J Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1001/archderm.134.3.376","key":"doi240066r6","year":"1998","issue":"3","author":"White","volume":"134","first-page":"376","unstructured":null,"article-title":"Recurrence rates after the first course of isotretinoin.","journal-title":"Arch Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1159/000018130","key":"doi240066r7","year":"1999","issue":"3","author":"Lehucher-Ceyrac","volume":"198","first-page":"278","unstructured":null,"article-title":"Predictive factors for failure of isotretinoin treatment in acne patients: results from a cohort of 237 patients.","journal-title":"Dermatology","doi-asserted-by":"publisher"},{"DOI":null,"key":"doi240066r8","year":"2005","issue":"3","author":"Al-Mutairi","volume":"4","first-page":"369","unstructured":null,"article-title":"Isotretinoin in acne vulgaris: a prospective analysis of 160 cases from Kuwait.","journal-title":"J Drugs Dermatol","doi-asserted-by":null},{"DOI":"10.1159/000090658","key":"doi240066r9","year":"2006","issue":"2","author":"Quéreux","volume":"212","first-page":"168","unstructured":null,"article-title":"Prospective study of risk factors of relapse after treatment of acne with oral isotretinoin.","journal-title":"Dermatology","doi-asserted-by":"publisher"},{"DOI":"10.1111/j.1365-2133.2007.08250.x","key":"doi240066r10","year":"2007","issue":"6","author":"Azoulay","volume":"157","first-page":"1240","unstructured":null,"article-title":"Isotretinoin therapy and the incidence of acne relapse: a nested case-control study.","journal-title":"Br J Dermatol","doi-asserted-by":"publisher"},{"DOI":null,"key":"doi240066r11","year":"2008","issue":"10","author":"Liu","volume":"7","first-page":"963","unstructured":null,"article-title":"Relapse of acne following isotretinoin treatment: a retrospective study of 405 patients.","journal-title":"J Drugs Dermatol","doi-asserted-by":null},{"DOI":"10.1159/000249320","key":"doi240066r12","year":"1986","issue":"3","author":"Harms","volume":"172","first-page":"148","unstructured":null,"article-title":"The relapses of cystic acne after isotretinoin treatment are age-related: a long-term follow-up study.","journal-title":"Dermatologica","doi-asserted-by":"publisher"},{"DOI":"10.1111/j.1468-3083.2010.03933.x","key":"doi240066r13","year":"2011","issue":"9","author":"Borghi","volume":"25","first-page":"1094","unstructured":null,"article-title":"Low-cumulative dose isotretinoin treatment in mild-to-moderate acne: efficacy in achieving stable remission.","journal-title":"J Eur Acad Dermatol Venereol","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jaad.2010.06.025","key":"doi240066r14","year":"2011","issue":"2","author":"Coloe","volume":"65","first-page":"422","unstructured":null,"article-title":"Could higher doses of isotretinoin reduce the frequency of treatment failure in patients with acne?","journal-title":"J Am Acad Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1001/jamadermatol.2013.6746","key":"doi240066r15","year":"2013","issue":"12","author":"Blasiak","volume":"149","first-page":"1392","unstructured":null,"article-title":"High-dose isotretinoin treatment and the rate of retrial, relapse, and adverse effects in patients with acne vulgaris.","journal-title":"JAMA Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.ad.2012.05.004","key":"doi240066r16","year":"2013","issue":"1","author":"Morales-Cardona","volume":"104","first-page":"61","unstructured":null,"article-title":"Acne relapse rate and predictors of relapse following treatment with oral isotretinoin.","journal-title":"Actas Dermosifiliogr","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jaad.2019.06.1293","key":"doi240066r17","year":"2020","issue":"5","author":"Fernandez","volume":"82","first-page":"1218","unstructured":null,"article-title":"Retrospective case series of isotretinoin outcomes for acne in 393 female patients at Baylor College of Medicine during 2012-2016.","journal-title":"J Am Acad Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1111/dth.15109","key":"doi240066r18","year":"2021","issue":"6","author":"Demirci Saadet","volume":"34","first-page":null,"unstructured":null,"article-title":"Investigation of relapse rate and factors affecting relapse after oral isotretinoin treatment in patients with acne vulgaris.","journal-title":"Dermatol Ther","doi-asserted-by":"publisher"},{"DOI":"10.3389/fphar.2021.733526","key":"doi240066r19","year":"2021","issue":null,"author":"Skroza","volume":"12","first-page":null,"unstructured":null,"article-title":"Advantages of tailored isotretinoin treatment in moderate to severe acne: real-life data.","journal-title":"Front Pharmacol","doi-asserted-by":"publisher"},{"DOI":"10.1055/s-0038-1673354","key":"doi240066r20","year":"2019","issue":"1","author":"Kulaylat","volume":"32","first-page":"54","unstructured":null,"article-title":"Truven Health Analytics MarketScan databases for clinical research in colon and rectal surgery.","journal-title":"Clin Colon Rectal Surg","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jaad.2020.04.145","key":"doi240066r21","year":"2020","issue":"5","author":"Tripathi","volume":"83","first-page":"1546","unstructured":null,"article-title":"Big data in dermatology: publicly available health care databases for population health research.","journal-title":"J Am Acad Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1001/jamadermatol.2023.2363","key":"doi240066r22","year":"2023","issue":"10","author":"Barbieri","volume":"159","first-page":"1135","unstructured":null,"article-title":"Temporal trends in the use of systemic medications for acne from 2017 to 2020.","journal-title":"JAMA Dermatol","doi-asserted-by":"publisher"},{"DOI":null,"key":"doi240066r23","year":"2021","issue":"36","author":"Fryar","volume":null,"first-page":"1","unstructured":null,"article-title":"Anthropometric reference data for children and adults: United States, 2015-2018.","journal-title":"Vital Health Stat 3","doi-asserted-by":null},{"DOI":"10.4103/0019-5154.131455","key":"doi240066r24","year":"2014","issue":"3","author":"Rao","volume":"59","first-page":"316","unstructured":null,"article-title":"Safety and efficacy of low-dose isotretinoin in the treatment of moderate to severe acne vulgaris.","journal-title":"Indian J Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1111/j.1440-0960.2012.00947.x","key":"doi240066r25","year":"2013","issue":"3","author":"Rademaker","volume":"54","first-page":"157","unstructured":null,"article-title":"Isotretinoin: dose, duration and relapse. What does 30 years of usage tell us?","journal-title":"Australas J Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1002/jvc2.154","key":"doi240066r26","year":"2023","issue":"3","author":"Daly","volume":"2","first-page":"432","unstructured":null,"article-title":"A systematic review of isotretinoin dosing in acne vulgaris.","journal-title":"JEADV Clin Pract","doi-asserted-by":"publisher"},{"DOI":"10.1111/j.1365-2133.2010.10152.x","key":"doi240066r27","year":"2011","issue":"6","author":"Lee","volume":"164","first-page":"1369","unstructured":null,"article-title":"Effectiveness of conventional, low-dose and intermittent oral isotretinoin in the treatment of acne: a randomized, controlled comparative study.","journal-title":"Br J Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1371/journal.pone.0210445","key":"doi240066r28","year":"2019","issue":"3","author":"Charrow","volume":"14","first-page":null,"unstructured":null,"article-title":"Differences in isotretinoin start, interruption, and early termination across race and sex in the iPLEDGE era.","journal-title":"PLoS One","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jaad.2007.06.045","key":"doi240066r29","year":"2008","issue":"1","author":"Collier","volume":"58","first-page":"56","unstructured":null,"article-title":"The prevalence of acne in adults 20 years and older.","journal-title":"J Am Acad Dermatol","doi-asserted-by":"publisher"},{"DOI":null,"key":"doi240066r30","year":"1997","issue":"10","author":"Lehucher-Ceyrac","volume":"124","first-page":"692","unstructured":null,"article-title":"[Acne, hyperandrogenism and oral isotretinoin resistance. 23 cases. Therapeutic implications].","journal-title":"Ann Dermatol Venereol","doi-asserted-by":null},{"DOI":"10.1111/j.1365-4632.2012.05691.x","key":"doi240066r31","year":"2013","issue":"3","author":"Cakir","volume":"52","first-page":"371","unstructured":null,"article-title":"Isotretinoin treatment in nodulocystic acne with and without polycystic ovary syndrome: efficacy and determinants of relapse.","journal-title":"Int J Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1371/journal.pone.0290763","key":"doi240066r32","year":"2023","issue":"9","author":"Chang","volume":"18","first-page":null,"unstructured":null,"article-title":"Acne accounts for an almost 2.5-fold higher proportion of dermatology visits among adult females compared to adult males in the United States: a study of the national ambulatory medical care survey from 2002-2016.","journal-title":"PLoS One","doi-asserted-by":"publisher"},{"DOI":"10.1111/ijd.12942","key":"doi240066r33","year":"2016","issue":"5","author":"Rademaker","volume":"55","first-page":"518","unstructured":null,"article-title":"Making sense of the effects of the cumulative dose of isotretinoin in acne vulgaris.","journal-title":"Int J Dermatol","doi-asserted-by":"publisher"}],"short-title":[],"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4,1]]}},"content-domain":{"domain":[],"crossmark-restriction":false},"original-title":[],"container-title":["JAMA Dermatology"],"published-print":{"date-parts":[[2025,4,1]]},"reference-count":33,"published-online":null,"references-count":33,"short-container-title":["JAMA Dermatol"],"is-referenced-by-count":1},"unpaywall":{"doi":"10.1001/jamadermatol.2024.5416","is_oa":false,"title":"Acne Relapse and Isotretinoin Retrial in Patients With Acne","updated":"2025-08-04T14:10:34+00:00","published_date":"2025-01-15","best_oa_location":null}},"created_at":"2025-09-19T22:06:30.810Z","updated_at":"2025-09-20T05:46:34.060Z","tags":[{"paper_doi":"10.1001/jamadermatol.2024.5416","tag_type":"age_group","value":"mixed","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2024.5416","tag_type":"category","value":"Dermatology","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2024.5416","tag_type":"condition","value":"Acne Vulgaris","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2024.5416","tag_type":"generic","value":"isotretinoin","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2024.5416","tag_type":"level_of_evidence","value":"3","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2024.5416","tag_type":"modality","value":"Oral Retinoid","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2024.5416","tag_type":"sample_size","value":"n=19,907","value_numeric":19907},{"paper_doi":"10.1001/jamadermatol.2024.5416","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2024.5416","tag_type":"study_design","value":"Retrospective Cohort","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2024.5416","tag_type":"warning","value":"Daily dose associations were evaluated among patients with cumulative dose ≥120 mg/kg per the abstract.","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2024.5416","tag_type":"warning","value":"Findings are from a commercial claims cohort; clinical definitions of relapse and dosing thresholds are abstract-level only.","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2024.5416","tag_type":"warning","value":"Study design classification is based on the abstract; full methodological details were not reviewed here.","value_numeric":null}],"summaries":{"what_studied":"A claims-based cohort study (MarketScan, 2017-2020) evaluated which factors were associated with acne relapse and isotretinoin retrial in patients aged 12 years or older who completed at least 4 months of isotretinoin and had at least 1 year of continuous enrollment after treatment. Multivariable Cox models examined sex, cumulative isotretinoin dose (mg/kg), and daily dose in relation to relapse and retrial.","key_result":"Of 19,907 patients, 4,482 (22.5%) relapsed and 1,639 (8.2%) underwent isotretinoin retrial. Female sex increased relapse risk (HR 1.43; 95% CI, 1.35-1.52) but decreased retrial (HR 0.68; 95% CI, 0.62-0.76); higher cumulative dose reduced relapse (HR 0.996 per mg/kg; 95% CI, 0.995-0.997) and retrial (HR 0.99 per mg/kg; 95% CI, 0.98-0.99), with lower retrial in low (<120 mg/kg) and conventional (120-220 mg/kg) but not high (>220 mg/kg) cumulative dose groups; daily or maximum daily dose was not associated with lower risk when cumulative dose was ≥120 mg/kg.","practice_takeaway":"Prioritize achieving an adequate cumulative isotretinoin dose to lower relapse and the need for retrial; increasing daily dose above conventional targets did not add protection once cumulative dose reached ≥120 mg/kg. Daily dosing can be individualized to patient preferences and tolerability without sacrificing relapse prevention at conventional or higher cumulative doses."}},{"doi":"10.1016/j.jaad.2023.12.017","pmid":"38300170","title":"Guidelines of care for the management of acne vulgaris","journal_title":"Journal of the American Academy of Dermatology","journal_issn":"0190-9622","published_at":"2024-02-01T00:00:00.000Z","url":"https://doi.org/10.1016/j.jaad.2023.12.017","source_score":374,"is_retracted":false,"is_open_access":true,"raw_metadata":{"ooir":{"day":"2024-04-16","doi":"10.1016/j.jaad.2023.12.017","days":"30","issn":"0190-9622","rank":"1","field":"Clinical Medicine","score":"374","category":"Dermatology","categories":["Dermatology"],"_categories":["Dermatology"]},"pubmed":{"doi":"10.1016/j.jaad.2023.12.017","title":"Guidelines of care for the management of acne vulgaris.","journal":"Journal of the American Academy of Dermatology","methods":"","results":"This guideline presents 18 evidence-based recommendations and 5 good practice statements. Strong recommendations are made for benzoyl peroxide, topical retinoids, topical antibiotics, and oral doxycycline. Oral isotretinoin is strongly recommended for acne that is severe, causing psychosocial burden or scarring, or failing standard oral or topical therapy. Conditional recommendations are made for topical clascoterone, salicylic acid, and azelaic acid, as well as for oral minocycline, sarecycline, combined oral contraceptive pills, and spironolactone. Combining topical therapies with multiple mechanisms of action, limiting systemic antibiotic use, combining systemic antibiotics with topical therapies, and adding intralesional corticosteroid injections for larger acne lesions are recommended as good practice statements.","abstract":"$33","keywords":["Acne","Cutibacterium acnes","acne vulgaris","adapalene","antiandrogens","antibiotics","azelaic acid","azithromycin","benzoyl peroxide","clascoterone","clindamycin","contraceptives","corticosteroids","diet and acne","doxycycline","erythromycin","grading and classification of acne","guidelines","hormonal therapy","isotretinoin","light therapies","microbiological and endocrine testing","minocycline","retinoids","salicylic acid","sarecycline","spironolactone","tazarotene","treatment","tretinoin","trifarotene"],"pubmed_id":"38300170","conclusions":"","publication_date":"2024-02-01T00:00:00"},"crossref":{"DOI":"10.1016/j.jaad.2023.12.017","URL":"https://doi.org/10.1016/j.jaad.2023.12.017","ISSN":["0190-9622"],"link":[{"URL":"https://api.elsevier.com/content/article/PII:S0190962223033893?httpAccept=text/xml","content-type":"text/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https://api.elsevier.com/content/article/PII:S0190962223033893?httpAccept=text/plain","content-type":"text/plain","content-version":"vor","intended-application":"text-mining"}],"page":"1006.e1-1006.e30","type":"journal-article","issue":"5","score":1,"title":["Guidelines of care for the management of acne vulgaris"],"author":[{"given":"Rachel V.","family":"Reynolds","sequence":"first","affiliation":[]},{"given":"Howa","family":"Yeung","sequence":"additional","affiliation":[]},{"given":"Carol E.","family":"Cheng","sequence":"additional","affiliation":[]},{"given":"Fran","family":"Cook-Bolden","sequence":"additional","affiliation":[]},{"given":"Seemal R.","family":"Desai","sequence":"additional","affiliation":[]},{"given":"Kelly M.","family":"Druby","sequence":"additional","affiliation":[]},{"given":"Esther E.","family":"Freeman","sequence":"additional","affiliation":[]},{"given":"Jonette E.","family":"Keri","sequence":"additional","affiliation":[]},{"given":"Linda F.","family":"Stein Gold","sequence":"additional","affiliation":[]},{"given":"Jerry K.L.","family":"Tan","sequence":"additional","affiliation":[]},{"given":"Megha M.","family":"Tollefson","sequence":"additional","affiliation":[]},{"given":"Jonathan S.","family":"Weiss","sequence":"additional","affiliation":[]},{"given":"Peggy A.","family":"Wu","sequence":"additional","affiliation":[]},{"given":"Andrea L.","family":"Zaenglein","sequence":"additional","affiliation":[]},{"given":"Jung Min","family":"Han","sequence":"additional","affiliation":[]},{"given":"John S.","family":"Barbieri","sequence":"additional","affiliation":[]}],"funder":[{"id":[{"id":"10.13039/100001934","id-type":"DOI","asserted-by":"publisher"}],"DOI":"10.13039/100001934","name":"American Academy of Dermatology","doi-asserted-by":"publisher"}],"issued":{"date-parts":[[2024,5]]},"member":"78","prefix":"10.1016","source":"Crossref","volume":"90","created":{"date-time":"2024-01-30T08:25:55Z","timestamp":1706603155000,"date-parts":[[2024,1,30]]},"indexed":{"date-time":"2025-09-20T07:51:25Z","timestamp":1758354685137,"date-parts":[[2025,9,20]]},"license":[{"URL":"https://www.elsevier.com/tdm/userlicense/1.0/","start":{"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000,"date-parts":[[2024,5,1]]},"delay-in-days":0,"content-version":"tdm"},{"URL":"https://www.elsevier.com/legal/tdmrep-license","start":{"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000,"date-parts":[[2024,5,1]]},"delay-in-days":0,"content-version":"tdm"}],"subject":[],"abstract":null,"language":"en","relation":{},"resource":{"primary":{"URL":"https://linkinghub.elsevier.com/retrieve/pii/S0190962223033893"}},"subtitle":[],"assertion":[{"name":"publisher","label":"This article is maintained by","value":"Elsevier"},{"name":"articletitle","label":"Article Title","value":"Guidelines of care for the management of acne vulgaris"},{"name":"journaltitle","label":"Journal Title","value":"Journal of the American Academy of Dermatology"},{"name":"articlelink","label":"CrossRef DOI link to publisher maintained version","value":"https://doi.org/10.1016/j.jaad.2023.12.017"},{"name":"content_type","label":"Content Type","value":"article"},{"name":"copyright","label":"Copyright","value":"© 2024 by the American Academy of Dermatology, Inc."}],"deposited":{"date-time":"2024-06-05T21:02:34Z","timestamp":1717621354000,"date-parts":[[2024,6,5]]},"issn-type":[{"type":"print","value":"0190-9622"}],"published":{"date-parts":[[2024,5]]},"publisher":"Elsevier BV","reference":[{"DOI":"10.1016/j.jaad.2016.12.043","key":"10.1016/j.jaad.2023.12.017_bib1","year":"2017","issue":null,"author":"Lim","volume":"76","first-page":"958","unstructured":null,"article-title":"The burden of skin disease in the United States","journal-title":"J Am Acad Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1111/bjd.20882","key":"10.1016/j.jaad.2023.12.017_bib2","year":"2022","issue":null,"author":"Chen","volume":"186","first-page":"673","unstructured":null,"article-title":"Magnitude and temporal trend of acne vulgaris burden in 204 countries and territories from 1990 to 2019: an analysis from the global burden of disease study 2019","journal-title":"Br J Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.jaad.2015.12.037","key":"10.1016/j.jaad.2023.12.017_bib3","year":"2016","issue":null,"author":"Zaenglein","volume":"74","first-page":"945","unstructured":null,"article-title":"Guidelines of care for the management of acne vulgaris","journal-title":"J Am Acad Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1542/peds.2013-0490B","key":"10.1016/j.jaad.2023.12.017_bib4","year":"2013","issue":"Suppl 3","author":"Eichenfield","volume":"131","first-page":"S163","unstructured":null,"article-title":"Evidence-based recommendations for the diagnosis and treatment of pediatric acne","journal-title":"Pediatrics","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.jclinepi.2012.03.013","key":"10.1016/j.jaad.2023.12.017_bib5","year":"2013","issue":null,"author":"Andrews","volume":"66","first-page":"719","unstructured":null,"article-title":"GRADE guidelines: 14. Going from evidence to recommendations: the significance and presentation of recommendations","journal-title":"J Clin Epidemiol","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.jclinepi.2013.02.003","key":"10.1016/j.jaad.2023.12.017_bib6","year":"2013","issue":null,"author":"Andrews","volume":"66","first-page":"726","unstructured":null,"article-title":"GRADE guidelines: 15. Going from evidence to recommendation-determinants of a recommendation's direction and strength","journal-title":"J Clin Epidemiol","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.jclinepi.2016.07.006","key":"10.1016/j.jaad.2023.12.017_bib7","year":"2016","issue":null,"author":"Guyatt","volume":"80","first-page":"3","unstructured":null,"article-title":"Guideline panels should seldom make good practice statements: guidance from the GRADE Working Group","journal-title":"J Clin Epidemiol","doi-asserted-by":"crossref"},{"DOI":"10.1001/jama.2021.17633","key":"10.1016/j.jaad.2023.12.017_bib8","year":"2021","issue":null,"author":"Eichenfield","volume":"326","first-page":"2055","unstructured":null,"article-title":"Management of acne vulgaris: a review","journal-title":"JAMA","doi-asserted-by":"crossref"},{"DOI":"10.1038/jid.2013.446","key":"10.1016/j.jaad.2023.12.017_bib9","year":"2014","issue":null,"author":"Hay","volume":"134","first-page":"1527","unstructured":null,"article-title":"The global burden of skin disease in 2010: an analysis of the prevalence and impact of skin conditions","journal-title":"J Invest Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1111/bjd.12149","key":"10.1016/j.jaad.2023.12.017_bib10","year":"2013","issue":null,"author":"Bhate","volume":"168","first-page":"474","unstructured":null,"article-title":"Epidemiology of acne vulgaris","journal-title":"Br J Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1001/jamadermatol.2016.5538","key":"10.1016/j.jaad.2023.12.017_bib11","year":"2017","issue":null,"author":"Karimkhani","volume":"153","first-page":"406","unstructured":null,"article-title":"Global skin disease morbidity and mortality: an update from the global burden of disease study 2013","journal-title":"JAMA Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1016/S0190-9622(98)70442-6","key":"10.1016/j.jaad.2023.12.017_bib12","year":"1998","issue":null,"author":"White","volume":"39","first-page":"S34","unstructured":null,"article-title":"Recent findings in the epidemiologic evidence, classification, and subtypes of acne vulgaris","journal-title":"J Am Acad Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1007/s13555-018-0224-7","key":"10.1016/j.jaad.2023.12.017_bib13","year":"2018","issue":null,"author":"Fabbrocini","volume":"8","first-page":"85","unstructured":null,"article-title":"A qualitative investigation of the impact of acne on health-related quality of life (HRQL): development of a conceptual model","journal-title":"Dermatol Ther","doi-asserted-by":"crossref"},{"DOI":"10.1001/jamadermatol.2021.2185","key":"10.1016/j.jaad.2023.12.017_bib14","year":"2021","issue":null,"author":"Barbieri","volume":"157","first-page":"1040","unstructured":null,"article-title":"Patient perspectives on the lived experience of acne and its treatment among adult women with acne: a qualitative study","journal-title":"JAMA Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1046/j.1365-2133.1999.02768.x","key":"10.1016/j.jaad.2023.12.017_bib15","year":"1999","issue":null,"author":"Mallon","volume":"140","first-page":"672","unstructured":null,"article-title":"The quality of life in acne: a comparison with general medical conditions using generic questionnaires","journal-title":"Br J Dermatol","doi-asserted-by":"crossref"},{"DOI":null,"key":"10.1016/j.jaad.2023.12.017_bib16","year":"2014","issue":null,"author":"Cresce","volume":"13","first-page":"692","unstructured":null,"article-title":"The quality of life impact of acne and rosacea compared to other major medical conditions","journal-title":"J Drugs Dermatol","doi-asserted-by":null},{"DOI":"10.1046/j.1365-2133.1998.02511.x","key":"10.1016/j.jaad.2023.12.017_bib17","year":"1998","issue":null,"author":"Gupta","volume":"139","first-page":"846","unstructured":null,"article-title":"Depression and suicidal ideation in dermatology patients with acne, alopecia areata, atopic dermatitis and psoriasis","journal-title":"Br J Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1111/j.1471-6712.2007.00547.x","key":"10.1016/j.jaad.2023.12.017_bib18","year":"2008","issue":null,"author":"Magin","volume":"22","first-page":"430","unstructured":null,"article-title":"Experiences of appearance-related teasing and bullying in skin diseases and their psychological sequelae: results of a qualitative study","journal-title":"Scand J Caring Sci","doi-asserted-by":"crossref"},{"DOI":"10.1186/1751-0759-5-11","key":"10.1016/j.jaad.2023.12.017_bib19","year":"2011","issue":null,"author":"Ritvo","volume":"5","first-page":"11","unstructured":null,"article-title":"Psychosocial judgements and perceptions of adolescents with acne vulgaris: a blinded, controlled comparison of adult and peer evaluations","journal-title":"Biopsychosoc Med","doi-asserted-by":"crossref"},{"DOI":"10.1111/j.1440-1754.2006.00979.x","key":"10.1016/j.jaad.2023.12.017_bib20","year":"2006","issue":null,"author":"Purvis","volume":"42","first-page":"793","unstructured":null,"article-title":"Acne, anxiety, depression and suicide in teenagers: a cross-sectional survey of New Zealand secondary school students","journal-title":"J Paediatr Child Health","doi-asserted-by":"crossref"},{"DOI":"10.1038/s41598-020-62715-3","key":"10.1016/j.jaad.2023.12.017_bib21","year":"2020","issue":null,"author":"Heng","volume":"10","first-page":"5754","unstructured":null,"article-title":"Systematic review of the epidemiology of acne vulgaris","journal-title":"Sci Rep","doi-asserted-by":"crossref"},{"DOI":"10.1111/jebm.12249","key":"10.1016/j.jaad.2023.12.017_bib22","year":"2017","issue":null,"author":"Layton","volume":"10","first-page":"163","unstructured":null,"article-title":"Prioritizing treatment outcomes: how people with acne vulgaris decide if their treatment is working","journal-title":"J Evid Based Med","doi-asserted-by":"crossref"},{"DOI":null,"key":"10.1016/j.jaad.2023.12.017_bib23","year":"2005","issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":"10.3109/09546639809160698","key":"10.1016/j.jaad.2023.12.017_bib24","year":"1998","issue":null,"author":"O'Brien","volume":"9","first-page":"215","unstructured":null,"article-title":"The Leeds revised acne grading system","journal-title":"J Dermatol Treat","doi-asserted-by":"crossref"},{"DOI":"10.1046/j.1365-4362.1997.00099.x","key":"10.1016/j.jaad.2023.12.017_bib25","year":"1997","issue":null,"author":"Doshi","volume":"36","first-page":"416","unstructured":null,"article-title":"A comparison of current acne grading systems and proposal of a novel system","journal-title":"Int J Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1111/j.1468-3083.2010.03685.x","key":"10.1016/j.jaad.2023.12.017_bib26","year":"2011","issue":null,"author":"Dreno","volume":"25","first-page":"43","unstructured":null,"article-title":"Development and evaluation of a global acne severity scale (GEA scale) suitable for France and Europe","journal-title":"J Eur Acad Dermatol Venereol","doi-asserted-by":"crossref"},{"DOI":"10.2310/7750.2007.00037","key":"10.1016/j.jaad.2023.12.017_bib27","year":"2007","issue":null,"author":"Tan","volume":"11","first-page":"211","unstructured":null,"article-title":"Development and validation of a comprehensive acne severity scale","journal-title":"J Cutan Med Surg","doi-asserted-by":"crossref"},{"DOI":"10.1111/pde.13262","key":"10.1016/j.jaad.2023.12.017_bib28","year":"2017","issue":null,"author":"Patel","volume":"34","first-page":"656","unstructured":null,"article-title":"The patient-centered acne severity scale study","journal-title":"Pediatr Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1001/jamadermatol.2019.4668","key":"10.1016/j.jaad.2023.12.017_bib29","year":"2020","issue":null,"author":"Bernardis","volume":"156","first-page":"296","unstructured":null,"article-title":"Development and initial validation of a multidimensional acne global grading system integrating primary lesions and secondary changes","journal-title":"JAMA Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1111/1346-8138.15613","key":"10.1016/j.jaad.2023.12.017_bib30","year":"2021","issue":null,"author":"Cho","volume":"48","first-page":"42","unstructured":null,"article-title":"Analysis of trends and status of physician-based evaluation methods in acne vulgaris from 2000 to 2019","journal-title":"J Dermatol","doi-asserted-by":"crossref"},{"DOI":null,"key":"10.1016/j.jaad.2023.12.017_bib31","year":"2016","issue":null,"author":"Stein Gold","volume":"15","first-page":"79","unstructured":null,"article-title":"Evolution of acne assessments and impact on acne medications: an evolving, imperfect paradigm","journal-title":"J Drugs Dermatol","doi-asserted-by":null},{"DOI":"10.1016/j.jaad.2013.07.029","key":"10.1016/j.jaad.2023.12.017_bib32","year":"2013","issue":null,"author":"Tan","volume":"69","first-page":"754","unstructured":null,"article-title":"Evaluation of essential clinical components and features of current acne global grading scales","journal-title":"J Am Acad Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.jaad.2011.09.005","key":"10.1016/j.jaad.2023.12.017_bib33","year":"2012","issue":null,"author":"Tan","volume":"67","first-page":"187","unstructured":null,"article-title":"Acne severity grading: determining essential clinical components and features using a Delphi consensus","journal-title":"J Am Acad Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.jaad.2018.09.017","key":"10.1016/j.jaad.2023.12.017_bib34","year":"2019","issue":null,"author":"Gottlieb","volume":"80","first-page":"823","unstructured":null,"article-title":"A provider global assessment quality measure for clinical practice for inflammatory skin disorders","journal-title":"J Am Acad Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.clindermatol.2016.10.006","key":"10.1016/j.jaad.2023.12.017_bib35","year":"2017","issue":null,"author":"Becker","volume":"35","first-page":"147","unstructured":null,"article-title":"Objective assessment of acne","journal-title":"Clin Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1111/jdv.14585","key":"10.1016/j.jaad.2023.12.017_bib36","year":"2018","issue":null,"author":"Chernyshov","volume":"32","first-page":"194","unstructured":null,"article-title":"Quality of life measurement in acne. Position paper of the European Academy of Dermatology and Venereology task forces on quality of life and patient oriented outcomes and acne, rosacea and hidradenitis suppurativa","journal-title":"J Eur Acad Dermatol Venereol","doi-asserted-by":"crossref"},{"DOI":"10.1007/s40257-019-00438-6","key":"10.1016/j.jaad.2023.12.017_bib37","year":"2019","issue":null,"author":"Marron","volume":"20","first-page":"527","unstructured":null,"article-title":"Quality-of-Life research in acne vulgaris: current status and future directions","journal-title":"Am J Clin Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1001/jamadermatol.2022.2260","key":"10.1016/j.jaad.2023.12.017_bib38","year":"2022","issue":null,"author":"Hopkins","volume":"158","first-page":"900","unstructured":null,"article-title":"Patient-reported outcome measures for health-related quality of life in patients with acne vulgaris: a systematic review of measure development and measurement properties","journal-title":"JAMA Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1038/jid.2013.21","key":"10.1016/j.jaad.2023.12.017_bib39","year":"2013","issue":null,"author":"Fitz-Gibbon","volume":"133","first-page":"2152","unstructured":null,"article-title":"Propionibacterium acnes strain populations in the human skin microbiome associated with acne","journal-title":"J Invest Dermatol","doi-asserted-by":"crossref"},{"DOI":null,"key":"10.1016/j.jaad.2023.12.017_bib40","year":"2010","issue":null,"author":"Miura","volume":"57","first-page":"65","unstructured":null,"article-title":"Quantitative PCR of Propionibacterium acnes DNA in samples aspirated from sebaceous follicles on the normal skin of subjects with or without acne","journal-title":"J Med Dent Sci","doi-asserted-by":null},{"DOI":"10.1111/1346-8138.13245","key":"10.1016/j.jaad.2023.12.017_bib41","year":"2016","issue":null,"author":"Akaza","volume":"43","first-page":"906","unstructured":null,"article-title":"Microorganisms inhabiting follicular contents of facial acne are not only Propionibacterium but also Malassezia spp","journal-title":"J Dermatol","doi-asserted-by":"crossref"},{"DOI":null,"key":"10.1016/j.jaad.2023.12.017_bib42","year":"2020","issue":null,"author":"Jusuf","volume":"13","first-page":"773","unstructured":null,"article-title":"Differences of microbiomes found in non-inflammatory and inflammatory lesions of acne vulgaris","journal-title":"Clin Cosmet Investig Dermatol","doi-asserted-by":null},{"DOI":"10.1111/exd.13296","key":"10.1016/j.jaad.2023.12.017_bib43","year":"2017","issue":null,"author":"Dreno","volume":"26","first-page":"798","unstructured":null,"article-title":"Skin microbiome and acne vulgaris: staphylococcus, a new actor in acne","journal-title":"Exp Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1007/s12275-021-0647-1","key":"10.1016/j.jaad.2023.12.017_bib44","year":"2021","issue":null,"author":"Kim","volume":"59","first-page":"369","unstructured":null,"article-title":"Inferences in microbial structural signatures of acne microbiome and mycobiome","journal-title":"J Microbiol","doi-asserted-by":"crossref"},{"DOI":"10.1159/000356777","key":"10.1016/j.jaad.2023.12.017_bib45","year":"2014","issue":null,"author":"Numata","volume":"228","first-page":"86","unstructured":null,"article-title":"Analysis of facial skin-resident microbiota in Japanese acne patients","journal-title":"Dermatology","doi-asserted-by":"crossref"},{"DOI":"10.1111/j.1346-8138.2006.00206.x","key":"10.1016/j.jaad.2023.12.017_bib46","year":"2006","issue":null,"author":"Ergin","volume":"33","first-page":"899","unstructured":null,"article-title":"Nasal antibiotic-resistant Propionibacterium acnes carriage in acne vulgaris patients in Turkey","journal-title":"J Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1111/j.1365-4632.2011.05371.x","key":"10.1016/j.jaad.2023.12.017_bib47","year":"2013","issue":null,"author":"Schafer","volume":"52","first-page":"418","unstructured":null,"article-title":"Antimicrobial susceptibility and genetic characteristics of Propionibacterium acnes isolated from patients with acne","journal-title":"Int J Dermatol","doi-asserted-by":"crossref"},{"DOI":null,"key":"10.1016/j.jaad.2023.12.017_bib48","year":"2018","issue":null,"author":"Franik","volume":"22","first-page":"4411","unstructured":null,"article-title":"Hormonal and metabolic aspects of acne vulgaris in women with polycystic ovary syndrome","journal-title":"Eur Rev Med Pharmacol Sci","doi-asserted-by":null},{"DOI":null,"key":"10.1016/j.jaad.2023.12.017_bib49","year":"2016","issue":null,"author":"Kiayani","volume":"28","first-page":"357","unstructured":null,"article-title":"Association of serum testosterone and sex hormone binding globulin levels in females with acne based on its severity","journal-title":"J Ayub Med Coll Abbottabad","doi-asserted-by":null},{"DOI":"10.1210/jc.2018-00241","key":"10.1016/j.jaad.2023.12.017_bib50","year":"2018","issue":null,"author":"Martin","volume":"103","first-page":"1233","unstructured":null,"article-title":"Evaluation and treatment of hirsutism in premenopausal women: an endocrine society clinical practice guideline","journal-title":"J Clin Endocrinol Metab","doi-asserted-by":"crossref"},{"DOI":"10.1111/j.1365-4632.2007.03411.x","key":"10.1016/j.jaad.2023.12.017_bib51","year":"2007","issue":null,"author":"Seirafi","volume":"46","first-page":"1188","unstructured":null,"article-title":"Assessment of androgens in women with adult-onset acne","journal-title":"Int J Dermatol","doi-asserted-by":"crossref"},{"DOI":null,"key":"10.1016/j.jaad.2023.12.017_bib52","year":"1990","issue":null,"author":"Schmidt","volume":"24","first-page":"457","unstructured":null,"article-title":"Endocrine parameters in acne vulgaris","journal-title":"Endocrinol Exp","doi-asserted-by":null},{"DOI":"10.1111/1523-1747.ep12539043","key":"10.1016/j.jaad.2023.12.017_bib53","year":"1983","issue":null,"author":"Lucky","volume":"81","first-page":"70","unstructured":null,"article-title":"Plasma androgens in women with acne vulgaris","journal-title":"J Invest Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1111/j.1346-8138.1997.tb02778.x","key":"10.1016/j.jaad.2023.12.017_bib54","year":"1997","issue":null,"author":"Timpatanapong","volume":"24","first-page":"223","unstructured":null,"article-title":"Hormonal profiles and prevalence of polycystic ovary syndrome in women with acne","journal-title":"J Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.clinbiochem.2010.09.010","key":"10.1016/j.jaad.2023.12.017_bib55","year":"2010","issue":null,"author":"Arora","volume":"43","first-page":"1415","unstructured":null,"article-title":"The relationship of lipid profile and menstrual cycle with acne vulgaris","journal-title":"Clin Biochem","doi-asserted-by":"crossref"},{"DOI":"10.1590/S0100-879X2009000600005","key":"10.1016/j.jaad.2023.12.017_bib56","year":"2009","issue":null,"author":"Abulnaja","volume":"42","first-page":"501","unstructured":null,"article-title":"Changes in the hormone and lipid profile of obese adolescent Saudi females with acne vulgaris","journal-title":"Braz J Med Biol Res","doi-asserted-by":"crossref"},{"DOI":null,"key":"10.1016/j.jaad.2023.12.017_bib57","year":"2012","issue":null,"author":"Saleh","volume":"33","first-page":"1196","unstructured":null,"article-title":"Role of growth hormone and insulin-like growth factor-I in hyperandrogenism and the severity of acne vulgaris in young males","journal-title":"Saudi Med J","doi-asserted-by":null},{"DOI":null,"key":"10.1016/j.jaad.2023.12.017_bib58","year":"2018","issue":"10","author":"Tyring","volume":"17","first-page":"1084","unstructured":null,"article-title":"Novel tretinoin 0.05% lotion for the once-daily treatment of moderate-to-severe acne vulgaris: assessment of efficacy and safety in patients aged 9 years and older","journal-title":"J Drugs Dermatol JDD","doi-asserted-by":null},{"DOI":"10.1016/j.jaad.2004.10.879","key":"10.1016/j.jaad.2023.12.017_bib59","year":"2006","issue":null,"author":"Thiboutot","volume":"54","first-page":"242","unstructured":null,"article-title":"Adapalene gel 0.3% for the treatment of acne vulgaris: a multicenter, randomized, double-blind, controlled, phase III trial","journal-title":"J Am Acad Dermatol","doi-asserted-by":"crossref"},{"DOI":null,"key":"10.1016/j.jaad.2023.12.017_bib60","year":"1999","issue":null,"author":"Shalita","volume":"63","first-page":"349","unstructured":null,"article-title":"Tazarotene gel is safe and effective in the treatment of acne vulgaris: a multicenter, double-blind, vehicle-controlled study","journal-title":"Cutis","doi-asserted-by":null},{"DOI":"10.36849/JDD.2020.3977","key":"10.1016/j.jaad.2023.12.017_bib61","year":"2020","issue":null,"author":"Tanghetti","volume":"19","first-page":"70","unstructured":null,"article-title":"Tazarotene 0.045% lotion for once-daily treatment of moderate-to-severe acne vulgaris: results from two phase 3 trials","journal-title":"J Drugs Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.jaad.2019.02.044","key":"10.1016/j.jaad.2023.12.017_bib62","year":"2019","issue":"6","author":"Tan","volume":"80","first-page":"1691","unstructured":null,"article-title":"Randomized phase 3 evaluation of trifarotene 50 mug/g cream treatment of moderate facial and truncal acne","journal-title":"J Am Acad Dermatol","doi-asserted-by":"crossref"},{"DOI":null,"key":"10.1016/j.jaad.2023.12.017_bib63","year":"2020","issue":"6","author":"Webster","volume":"18","first-page":"343","unstructured":null,"article-title":"Microencapsulated benzoyl peroxide and tretinoin for the treatment of acne vulgaris: results from a phase 2 multicenter, double-blind, randomized, vehicle-controlled study","journal-title":"Skinmed","doi-asserted-by":null},{"DOI":"10.1111/j.1365-2133.2009.09209.x","key":"10.1016/j.jaad.2023.12.017_bib64","year":"2009","issue":null,"author":"Gollnick","volume":"161","first-page":"1180","unstructured":null,"article-title":"Adapalene-benzoyl peroxide, a unique fixed-dose combination topical gel for the treatment of acne vulgaris: a transatlantic, randomized, double-blind, controlled study in 1670 patients","journal-title":"Br J Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1111/1346-8138.12580","key":"10.1016/j.jaad.2023.12.017_bib65","year":"2014","issue":"9","author":"Kawashima","volume":"41","first-page":"795","unstructured":null,"article-title":"Is benzoyl peroxide 3% topical gel effective and safe in the treatment of acne vulgaris in Japanese patients? A multicenter, randomized, double-blind, vehicle-controlled, parallel-group study","journal-title":"J Dermatol","doi-asserted-by":"crossref"},{"DOI":null,"key":"10.1016/j.jaad.2023.12.017_bib66","year":"2011","issue":null,"author":"Eichenfield","volume":"10","first-page":"1382","unstructured":null,"article-title":"Safety and efficacy of clindamycin phosphate 1.2%-benzoyl peroxide 3% fixed-dose combination gel for the treatment of acne vulgaris: a phase 3, multicenter, randomized, double-blind, active- and vehicle-controlled study","journal-title":"J Drugs Dermatol","doi-asserted-by":null},{"DOI":null,"key":"10.1016/j.jaad.2023.12.017_bib67","year":"1980","issue":null,"author":"Smith","volume":"25","first-page":"90","unstructured":null,"article-title":"Benzoyl peroxide lotion (20 percent) in acne","journal-title":"Cutis","doi-asserted-by":null},{"DOI":"10.1016/S0190-9622(83)70211-2","key":"10.1016/j.jaad.2023.12.017_bib68","year":"1983","issue":null,"author":"Chalker","volume":"9","first-page":"933","unstructured":null,"article-title":"A double-blind study of the effectiveness of a 3% erythromycin and 5% benzoyl peroxide combination in the treatment of acne vulgaris","journal-title":"J Am Acad Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1016/S0190-9622(97)70177-4","key":"10.1016/j.jaad.2023.12.017_bib69","year":"1997","issue":null,"author":"Lookingbill","volume":"37","first-page":"590","unstructured":null,"article-title":"Treatment of acne with a combination clindamycin/benzoyl peroxide gel compared with clindamycin gel, benzoyl peroxide gel and vehicle gel: combined results of two double-blind investigations","journal-title":"J Am Acad Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1111/j.1365-2230.1992.tb00196.x","key":"10.1016/j.jaad.2023.12.017_bib70","year":"1992","issue":null,"author":"Hughes","volume":"17","first-page":"165","unstructured":null,"article-title":"A double-blind evaluation of topical isotretinoin 0.05%, benzoyl peroxide gel 5% and placebo in patients with acne","journal-title":"Clin Exp Dermatol","doi-asserted-by":"crossref"},{"DOI":null,"key":"10.1016/j.jaad.2023.12.017_bib71","year":"2012","issue":null,"author":"Jarratt","volume":"11","first-page":"318","unstructured":null,"article-title":"Efficacy and safety of clindamycin-tretinoin gel versus clindamycin or tretinoin alone in acne vulgaris: a randomized, double-blind, vehicle-controlled study","journal-title":"J Drugs Dermatol","doi-asserted-by":null},{"DOI":"10.1111/j.1365-2133.2011.10332.x","key":"10.1016/j.jaad.2023.12.017_bib72","year":"2011","issue":null,"author":"Trifu","volume":"165","first-page":"177","unstructured":null,"article-title":"Cortexolone 17alpha-propionate 1% cream, a new potent antiandrogen for topical treatment of acne vulgaris. A pilot randomized, double-blind comparative study vs. placebo and tretinoin 0.05% cream","journal-title":"Br J Dermatol","doi-asserted-by":"crossref"},{"DOI":null,"key":"10.1016/j.jaad.2023.12.017_bib73","year":"2021","issue":null,"author":"Baldwin","volume":"14","first-page":"E53","unstructured":null,"article-title":"Tazarotene 0.045% lotion for moderate-to-severe acne in male and female participants: a phase II post-hoc analysis","journal-title":"J Clin Aesthet Dermatol","doi-asserted-by":null},{"DOI":null,"key":"10.1016/j.jaad.2023.12.017_bib74","year":"2019","issue":"11","author":"Lain","volume":"18","first-page":"1128","unstructured":null,"article-title":"Tretinoin 0.05% lotion for the once-daily treatment of moderate-to-severe acne vulgaris: impact of gender and Race on efficacy and safety","journal-title":"J Drugs Dermatol","doi-asserted-by":null},{"DOI":null,"key":"10.1016/j.jaad.2023.12.017_bib75","year":"2021","issue":"6","author":"Green","volume":"20","first-page":"608","unstructured":null,"article-title":"Tazarotene 0.045% lotion for moderate-to-severe acne patients: pooled phase 3 analysis by age and sex","journal-title":"J Drugs Dermatol","doi-asserted-by":null},{"DOI":null,"key":"10.1016/j.jaad.2023.12.017_bib76","year":"2019","issue":"12","author":"Stein Gold","volume":"18","first-page":"1218","unstructured":null,"article-title":"Tretinoin 0.05% lotion for the once-daily treatment of moderate and severe acne vulgaris in females: effect of age on efficacy and tolerability","journal-title":"J Drugs Dermatol","doi-asserted-by":null},{"DOI":null,"key":"10.1016/j.jaad.2023.12.017_bib77","year":"2020","issue":"2","author":"Paracha","volume":"34","first-page":"134","unstructured":null,"article-title":"Efficacy and safety of short term use of 0.1% tazarotene gel in the treatment of mild to moderate acne vulgaris: a randomized-vehicle controlled trial","journal-title":"J Postgrad Med Inst","doi-asserted-by":null},{"DOI":null,"key":"10.1016/j.jaad.2023.12.017_bib78","year":"2007","issue":null,"author":"Alirezai","volume":"17","first-page":"45","unstructured":null,"article-title":"Daily treatment with adapalene gel 0.1% maintains initial improvement of acne vulgaris previously treated with oral lymecycline","journal-title":"Eur J Dermatol","doi-asserted-by":null},{"DOI":"10.1159/000018255","key":"10.1016/j.jaad.2023.12.017_bib79","year":"1999","issue":null,"author":"Glass","volume":"199","first-page":"242","unstructured":null,"article-title":"A placebo-controlled clinical trial to compare a gel containing a combination of isotretinoin (0.05%) and erythromycin (2%) with gels containing isotretinoin (0.05%) or erythromycin (2%) alone in the topical treatment of acne vulgaris","journal-title":"Dermatology (Basel, Switzerland)","doi-asserted-by":"crossref"},{"DOI":null,"key":"10.1016/j.jaad.2023.12.017_bib80","year":"2019","issue":"6","author":"Tanghetti","volume":"18","first-page":"542","unstructured":null,"article-title":"A phase 2, multicenter, double-blind, randomized, vehicle-controlled clinical study to compare the safety and efficacy of a novel tazarotene 0.045% lotion and tazarotene 0.1% cream in the treatment of moderate-to-severe acne vulgaris","journal-title":"J Drugs Dermatol","doi-asserted-by":null},{"DOI":"10.1016/S0190-9622(87)70200-X","key":"10.1016/j.jaad.2023.12.017_bib81","year":"1987","issue":null,"author":"Chalker","volume":"17","first-page":"251","unstructured":null,"article-title":"Efficacy of topical isotretinoin 0.05% gel in acne vulgaris: results of a multicenter, double-blind investigation","journal-title":"J Am Acad Dermatol","doi-asserted-by":"crossref"},{"DOI":null,"key":"10.1016/j.jaad.2023.12.017_bib82","year":"2019","issue":"11","author":"Harper","volume":"18","first-page":"1147","unstructured":null,"article-title":"Efficacy and tolerability of a novel tretinoin 0.05% lotion for the once-daily treatment of moderate or severe acne vulgaris in adult females","journal-title":"J Drugs Dermatol","doi-asserted-by":null},{"DOI":null,"key":"10.1016/j.jaad.2023.12.017_bib83","year":"2007","issue":null,"author":"Lucky","volume":"6","first-page":"981","unstructured":null,"article-title":"Dapsone gel 5% for the treatment of acne vulgaris: safety and efficacy of long-term (1 year) treatment","journal-title":"J Drugs Dermatol","doi-asserted-by":null},{"DOI":null,"key":"10.1016/j.jaad.2023.12.017_bib84","year":"2016","issue":"8","author":"Eichenfield","volume":"15","first-page":"962","unstructured":null,"article-title":"Efficacy and safety of once-daily dapsone gel, 7.5% for treatment of adolescents and adults with acne vulgaris: second of two identically designed, large, multicenter, randomized, vehicle-controlled trials","journal-title":"J Drugs Dermatol","doi-asserted-by":null},{"DOI":null,"key":"10.1016/j.jaad.2023.12.017_bib85","year":"2016","issue":"5","author":"Stein Gold","volume":"15","first-page":"553","unstructured":null,"article-title":"Efficacy and safety of once-daily dapsone gel, 7.5% for treatment of adolescents and adults with acne vulgaris: first of two identically designed, large, multicenter, randomized, vehicle-controlled trials","journal-title":"J Drugs Dermatol","doi-asserted-by":null},{"DOI":null,"key":"10.1016/j.jaad.2023.12.017_bib86","year":"2018","issue":"11","author":"Alexis","volume":"11","first-page":"25","unstructured":null,"article-title":"BPX-01 minocycline topical gel shows promise for the treatment of moderate-tosevere inflammatory acne vulgaris","journal-title":"J Clin Aesthet Dermatol","doi-asserted-by":null},{"DOI":"10.1016/j.jaad.2019.05.078","key":"10.1016/j.jaad.2023.12.017_bib87","year":"2020","issue":"4","author":"Raoof","volume":"82","first-page":"832","unstructured":null,"article-title":"Efficacy and safety of a novel topical minocycline foam for the treatment of moderate to severe acne vulgaris: a phase 3 study","journal-title":"J Am Acad Dermatol","doi-asserted-by":"crossref"},{"DOI":null,"key":"10.1016/j.jaad.2023.12.017_bib88","year":"1988","issue":null,"author":"Pochi","volume":"41","first-page":"132","unstructured":null,"article-title":"Erythromycin 2 percent gel in the treatment of acne vulgaris","journal-title":"Cutis","doi-asserted-by":null},{"DOI":"10.1016/S0190-9622(80)80113-7","key":"10.1016/j.jaad.2023.12.017_bib89","year":"1980","issue":null,"author":"Dobson","volume":"3","first-page":"478","unstructured":null,"article-title":"Topical erythromycin solution in acne: results of a multiclinic trial","journal-title":"J Am Acad Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1016/S0190-9622(80)80044-2","key":"10.1016/j.jaad.2023.12.017_bib90","year":"1980","issue":null,"author":"Bernstein","volume":"2","first-page":"318","unstructured":null,"article-title":"Topically applied erythromycin in inflammatory acne vulgaris","journal-title":"J Am Acad Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1016/S0190-9622(85)70074-6","key":"10.1016/j.jaad.2023.12.017_bib91","year":"1985","issue":null,"author":"Lesher","volume":"12","first-page":"526","unstructured":null,"article-title":"An evaluation of a 2% erythromycin ointment in the topical therapy of acne vulgaris","journal-title":"J Am Acad Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1001/archderm.1981.01650080036024","key":"10.1016/j.jaad.2023.12.017_bib92","year":"1981","issue":null,"author":"Becker","volume":"117","first-page":"482","unstructured":null,"article-title":"Topical clindamycin therapy for acne vulgaris. A cooperative clinical study","journal-title":"Arch Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1001/jamadermatol.2020.0465","key":"10.1016/j.jaad.2023.12.017_bib93","year":"2020","issue":"6","author":"Hebert","volume":"156","first-page":"621","unstructured":null,"article-title":"Efficacy and safety of topical clascoterone cream, 1%, for treatment in patients with facial acne: two phase 3 randomized clinical trials","journal-title":"JAMA Dermatology","doi-asserted-by":"crossref"},{"DOI":null,"key":"10.1016/j.jaad.2023.12.017_bib94","year":"2019","issue":null,"author":"Mazzetti","volume":"1","first-page":"570","unstructured":null,"article-title":"A phase 2b, randomized, double-blind vehicle controlled, dose escalation study evaluating clascoterone 0.1%, 0.5%, and 1% topical cream in subjects with facial","journal-title":"Acne","doi-asserted-by":null},{"DOI":null,"key":"10.1016/j.jaad.2023.12.017_bib95","year":"1981","issue":null,"author":"Shalita","volume":"28","first-page":"556","unstructured":null,"article-title":"Treatment of mild and moderate acne vulgaris with salicylic acid in an alcohol-detergent vehicle","journal-title":"Cutis","doi-asserted-by":null},{"DOI":null,"key":"10.1016/j.jaad.2023.12.017_bib96","year":"1989","issue":null,"author":"Cunliffe","volume":"143","first-page":"31","unstructured":null,"article-title":"Clinical and laboratory studies on treatment with 20% azelaic acid cream for acne","journal-title":"Acta Derm Venereol Suppl","doi-asserted-by":null},{"DOI":null,"key":"10.1016/j.jaad.2023.12.017_bib97","year":"1989","issue":null,"author":"Katsambas","volume":"143","first-page":"35","unstructured":null,"article-title":"Clinical studies of 20% azelaic acid cream in the treatment of acne vulgaris. Comparison with vehicle and topical tretinoin","journal-title":"Acta Derm Venereol Suppl","doi-asserted-by":null},{"DOI":"10.4103/0378-6323.31892","key":"10.1016/j.jaad.2023.12.017_bib98","year":"2007","issue":null,"author":"Iraji","volume":"73","first-page":"94","unstructured":null,"article-title":"Efficacy of topical azelaic acid gel in the treatment of mild-moderate acne vulgaris","journal-title":"Indian J Dermatol Venereol Leprol","doi-asserted-by":"crossref"},{"DOI":"10.1007/s40257-021-00650-3","key":"10.1016/j.jaad.2023.12.017_bib99","year":"2022","issue":"1","author":"Stein Gold","volume":"23","first-page":"93","unstructured":null,"article-title":"Efficacy and safety of a fixed-dose clindamycin phosphate 1.2%, benzoyl peroxide 3.1%, and adapalene 0.15% gel for moderate-to-severe acne: a randomized phase II study of the first triple-combination drug","journal-title":"Am J Clin Dermatol","doi-asserted-by":"crossref"},{"DOI":null,"key":"10.1016/j.jaad.2023.12.017_bib100","year":"2015","issue":"4","author":"Harper","volume":"14","first-page":"381","unstructured":null,"article-title":"The efficacy and tolerability of a fixed combination clindamycin (1.2%) and benzoyl peroxide (3.75%) aqueous gel in patients with facial acne vulgaris: gender as a clinically relevant outcome variable","journal-title":"J Drugs Dermatol","doi-asserted-by":null},{"DOI":null,"key":"10.1016/j.jaad.2023.12.017_bib101","year":"2014","issue":"9","author":"Pariser","volume":"13","first-page":"1083","unstructured":null,"article-title":"An aqueous gel fixed combination of clindamycin phosphate 1.2% and benzoyl peroxide 3.75% for the once-daily treatment of moderate to severe acne vulgaris","journal-title":"J Drugs Dermatol","doi-asserted-by":null},{"DOI":null,"key":"10.1016/j.jaad.2023.12.017_bib102","year":"2015","issue":"5","author":"Cook-Bolden","volume":"8","first-page":"28","unstructured":null,"article-title":"Efficacy and tolerability of a fixed combination of clindamycin phosphate (1.2%) and benzoyl peroxide (3.75%) aqueous gel in moderate or severe adolescent acne vulgaris","journal-title":"J Clin Aesthet Dermatol","doi-asserted-by":null},{"DOI":null,"key":"10.1016/j.jaad.2023.12.017_bib103","year":"2015","issue":"12","author":"Gold","volume":"8","first-page":"22","unstructured":null,"article-title":"Sub-group analyses from a trial of a fixed combination of clindamycin phosphate 1.2% and benzoyl peroxide 3.75% gel for the treatment of moderate-to-severe acne vulgaris","journal-title":"J Clin Aesthet Dermatol","doi-asserted-by":null},{"DOI":null,"key":"10.1016/j.jaad.2023.12.017_bib104","year":"2015","issue":"9","author":"Stein Gold","volume":"14","first-page":"969","unstructured":null,"article-title":"Efficacy and tolerability of a fixed combination of clindamycin phosphate (1.2%) and benzoyl peroxide (3.75%) aqueous gel in moderate and severe acne vulgaris subpopulations","journal-title":"J Drugs Dermatol","doi-asserted-by":null},{"DOI":null,"key":"10.1016/j.jaad.2023.12.017_bib105","year":"2012","issue":null,"author":"Guerra-Tapia","volume":"11","first-page":"714","unstructured":null,"article-title":"Effects of benzoyl peroxide 5% clindamycin combination gel versus adapalene 0.1% on quality of life in patients with mild to moderate acne vulgaris: a randomized single-blind study","journal-title":"J Drugs Dermatol","doi-asserted-by":null},{"DOI":"10.1111/j.1365-2133.2007.08308.x","key":"10.1016/j.jaad.2023.12.017_bib106","year":"2008","issue":null,"author":"Langner","volume":"158","first-page":"122","unstructured":null,"article-title":"A randomized, single-blind comparison of topical clindamycin + benzoyl peroxide and adapalene in the treatment of mild to moderate facial acne vulgaris","journal-title":"Br J Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1080/09546634.2020.1720579","key":"10.1016/j.jaad.2023.12.017_bib107","year":"2021","issue":"8","author":"Dogra","volume":"32","first-page":"925","unstructured":null,"article-title":"Efficacy and safety comparison of combination of 0.04% tretinoin microspheres plus 1% clindamycin versus their monotherapy in patients with acne vulgaris: a phase 3, randomized, double-blind study","journal-title":"J Dermatolog Treat","doi-asserted-by":"crossref"},{"DOI":null,"key":"10.1016/j.jaad.2023.12.017_bib108","year":"2011","issue":null,"author":"Tanghetti","volume":"10","first-page":"783","unstructured":null,"article-title":"Clinical evidence for the role of a topical anti-inflammatory agent in comedonal acne: findings from a randomized study of dapsone gel 5% in combination with tazarotene cream 0.1% in patients with acne vulgaris","journal-title":"J Drugs Dermatol","doi-asserted-by":null},{"DOI":"10.1007/s40257-018-0352-y","key":"10.1016/j.jaad.2023.12.017_bib109","year":"2018","issue":"2","author":"Dreno","volume":"19","first-page":"275","unstructured":null,"article-title":"Prevention and reduction of atrophic acne scars with adapalene 0.3%/benzoyl peroxide 2.5% gel in subjects with moderate or severe facial acne: results of a 6-month randomized, vehicle-controlled trial using intra-individual comparison","journal-title":"Am J Clin Dermatol","doi-asserted-by":"crossref"},{"DOI":null,"key":"10.1016/j.jaad.2023.12.017_bib110","year":"2015","issue":"12","author":"Weiss","volume":"14","first-page":"1427","unstructured":null,"article-title":"Customized single-agent therapy management of severe inflammatory acne: a randomized, double-blind, parallel-group, controlled study of a new treatment - adapalene 0.3%-benzoyl peroxide 2.5% gel","journal-title":"J Drugs Dermatol","doi-asserted-by":null},{"DOI":"10.1007/s40257-016-0178-4","key":"10.1016/j.jaad.2023.12.017_bib111","year":"2016","issue":"3","author":"Stein Gold","volume":"17","first-page":"293","unstructured":null,"article-title":"Moderate and severe inflammatory acne vulgaris effectively treated with single-agent therapy by a new fixed-dose combination adapalene 0.3 %/benzoyl peroxide 2.5 % gel: a randomized, double-blind, parallel-group, controlled study","journal-title":"Am J Clin Dermatol","doi-asserted-by":"crossref"},{"DOI":null,"key":"10.1016/j.jaad.2023.12.017_bib112","year":"2017","issue":"6","author":"Stein Gold","volume":"16","first-page":"582","unstructured":null,"article-title":"Adapalene/benzoyl peroxide gel 0.3%/2.5%: effective acne therapy regardless of age or gender","journal-title":"J Drugs Dermatol","doi-asserted-by":null},{"DOI":"10.1111/1346-8138.12979","key":"10.1016/j.jaad.2023.12.017_bib113","year":"2015","issue":"11","author":"Kwon","volume":"42","first-page":"1058","unstructured":null,"article-title":"Do tutorials on application method enhance adapalene-benzoyl peroxide combination gel tolerability in the treatment of acne?","journal-title":"J Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1038/ajg.2010.303","key":"10.1016/j.jaad.2023.12.017_bib114","year":"2010","issue":null,"author":"Margolis","volume":"105","first-page":"2610","unstructured":null,"article-title":"Potential association between the oral tetracycline class of antimicrobials used to treat acne and inflammatory bowel disease","journal-title":"Am J Gastroenterol","doi-asserted-by":"crossref"},{"DOI":"10.1001/archderm.139.4.459","key":"10.1016/j.jaad.2023.12.017_bib115","year":"2003","issue":null,"author":"Skidmore","volume":"139","first-page":"459","unstructured":null,"article-title":"Effects of subantimicrobial-dose doxycycline in the treatment of moderate acne","journal-title":"Arch Dermatol","doi-asserted-by":"crossref"},{"DOI":null,"key":"10.1016/j.jaad.2023.12.017_bib116","year":"2013","issue":null,"author":"Leyden","volume":"12","first-page":"658","unstructured":null,"article-title":"A randomized, phase 2, dose-ranging study in the treatment of moderate to severe inflammatory facial acne vulgaris with doxycycline calcium","journal-title":"J Drugs Dermatol","doi-asserted-by":null},{"DOI":null,"key":"10.1016/j.jaad.2023.12.017_bib117","year":"2015","issue":null,"author":"Moore","volume":"14","first-page":"581","unstructured":null,"article-title":"Efficacy and safety of subantimicrobial dose, modified-release doxycycline 40 mg versus doxycycline 100 mg versus placebo for the treatment of inflammatory lesions in moderate and severe acne: a randomized, double-blinded, controlled study","journal-title":"J Drugs Dermatol","doi-asserted-by":null},{"DOI":"10.1001/archderm.1970.04000040057011","key":"10.1016/j.jaad.2023.12.017_bib118","year":"1970","issue":null,"author":"Plewig","volume":"101","first-page":"435","unstructured":null,"article-title":"Double-blind study of doxycycline in acne vulgaris","journal-title":"Arch Dermatol","doi-asserted-by":"crossref"},{"DOI":null,"key":"10.1016/j.jaad.2023.12.017_bib119","year":"2006","issue":null,"author":"Fleischer","volume":"78","first-page":"21","unstructured":null,"article-title":"Safety and efficacy of a new extended-release formulation of minocycline","journal-title":"Cutis","doi-asserted-by":null},{"DOI":null,"key":"10.1016/j.jaad.2023.12.017_bib120","year":"2006","issue":null,"author":"Stewart","volume":"78","first-page":"11","unstructured":null,"article-title":"Dose-ranging efficacy of new once-daily extended-release minocycline for acne vulgaris","journal-title":"Cutis","doi-asserted-by":null},{"DOI":"10.1016/j.jaad.2003.07.021","key":"10.1016/j.jaad.2023.12.017_bib121","year":"2004","issue":null,"author":"Leyden","volume":"50","first-page":"443","unstructured":null,"article-title":"A systemic type 15-reductase inhibitor is ineffective in the treatment of acne vulgaris","journal-title":"J Am Acad Dermatol","doi-asserted-by":"crossref"},{"DOI":null,"key":"10.1016/j.jaad.2023.12.017_bib122","year":"1976","issue":null,"author":"Hersle","volume":"19","first-page":"339","unstructured":null,"article-title":"Minocycline in acne vulgaris: a double-blind study","journal-title":"Curr Ther Res Clin Exp","doi-asserted-by":null},{"DOI":null,"key":"10.1016/j.jaad.2023.12.017_bib123","year":"2018","issue":null,"author":"Moore","volume":"17","first-page":"987","unstructured":null,"article-title":"Once-daily oral sarecycline 1.5 mg/kg/day is effective for moderate to severe acne vulgaris: results from two identically designed, phase 3, randomized, double-blind clinical trials","journal-title":"J Drugs Dermatol","doi-asserted-by":null},{"DOI":null,"key":"10.1016/j.jaad.2023.12.017_bib124","year":"2018","issue":null,"author":"Leyden","volume":"17","first-page":"333","unstructured":null,"article-title":"Efficacy and safety of sarecycline, a novel, once-daily, narrow spectrum antibiotic for the treatment of moderate to severe facial acne vulgaris: results of a phase 2, dose-ranging study","journal-title":"J Drugs Dermatol","doi-asserted-by":null},{"DOI":null,"key":"10.1016/j.jaad.2023.12.017_bib125","year":"2019","issue":null,"author":"Pariser","volume":"12","first-page":"E53","unstructured":null,"article-title":"Safety and tolerability of sarecycline for the treatment of acne vulgaris: results from a phase III, multicenter, open-Label study and a phase I phototoxicity study","journal-title":"J Clin Aesthet Dermatol","doi-asserted-by":null},{"DOI":null,"key":"10.1016/j.jaad.2023.12.017_bib126","year":"2011","issue":null,"author":"Maleszka","volume":"9","first-page":"86","unstructured":null,"article-title":"Pulsed azithromycin treatment is as effective and safe as 2-week-longer daily doxycycline treatment of acne vulgaris: a randomized, double-blind, noninferiority study","journal-title":"Skinmed","doi-asserted-by":null},{"DOI":"10.3109/09546631003762639","key":"10.1016/j.jaad.2023.12.017_bib127","year":"2011","issue":null,"author":"Babaeinejad","volume":"22","first-page":"206","unstructured":null,"article-title":"Comparison of therapeutic effects of oral doxycycline and azithromycin in patients with moderate acne vulgaris: what is the role of age?","journal-title":"J Dermatol Treat","doi-asserted-by":"crossref"},{"DOI":null,"key":"10.1016/j.jaad.2023.12.017_bib128","year":"2014","issue":null,"author":"Ullah","volume":"26","first-page":"64","unstructured":null,"article-title":"Comparison of oral azithromycin with oral doxycycline in the treatment of acne vulgaris","journal-title":"J Ayub Med Coll Abbottabad","doi-asserted-by":null},{"DOI":"10.1111/j.1365-2230.2005.01769.x","key":"10.1016/j.jaad.2023.12.017_bib129","year":"2005","issue":null,"author":"Kus","volume":"30","first-page":"215","unstructured":null,"article-title":"Comparison of efficacy of azithromycin vs. doxycycline in the treatment of acne vulgaris","journal-title":"Clin Exp Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1097/AOG.0b013e318187e1c5","key":"10.1016/j.jaad.2023.12.017_bib130","year":"2008","issue":null,"author":"Maloney","volume":"112","first-page":"773","unstructured":null,"article-title":"Treatment of acne using a 3-milligram drospirenone/20-microgram ethinyl estradiol oral contraceptive administered in a 24/4 regimen: a randomized controlled trial","journal-title":"Obstet Gynecol","doi-asserted-by":"crossref"},{"DOI":"10.1016/S0015-0282(01)01938-0","key":"10.1016/j.jaad.2023.12.017_bib131","year":"2001","issue":null,"author":"Thiboutot","volume":"76","first-page":"461","unstructured":null,"article-title":"A randomized, controlled trial of a low-dose contraceptive containing 20 microg of ethinyl estradiol and 100 microg of levonorgestrel for acne treatment","journal-title":"Fertil Steril","doi-asserted-by":"crossref"},{"DOI":"10.1067/mjd.2002.122192","key":"10.1016/j.jaad.2023.12.017_bib132","year":"2002","issue":null,"author":"Leyden","volume":"47","first-page":"399","unstructured":null,"article-title":"Efficacy of a low-dose oral contraceptive containing 20 microg of ethinyl estradiol and 100 microg of levonorgestrel for the treatment of moderate acne: a randomized, placebo-controlled trial","journal-title":"J Am Acad Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1016/S0029-7844(97)00059-8","key":"10.1016/j.jaad.2023.12.017_bib133","year":"1997","issue":null,"author":"Redmond","volume":"89","first-page":"615","unstructured":null,"article-title":"Norgestimate and ethinyl estradiol in the treatment of acne vulgaris: a randomized, placebo-controlled trial","journal-title":"Obstet Gynecol","doi-asserted-by":"crossref"},{"DOI":"10.1016/S0190-9622(97)70112-9","key":"10.1016/j.jaad.2023.12.017_bib134","year":"1997","issue":null,"author":"Lucky","volume":"37","first-page":"746","unstructured":null,"article-title":"Effectiveness of norgestimate and ethinyl estradiol in treating moderate acne vulgaris","journal-title":"J Am Acad Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.contraception.2008.10.010","key":"10.1016/j.jaad.2023.12.017_bib135","year":"2009","issue":null,"author":"Palombo-Kinne","volume":"79","first-page":"282","unstructured":null,"article-title":"Efficacy of a combined oral contraceptive containing 0.030 mg ethinylestradiol/2 mg dienogest for the treatment of papulopustular acne in comparison with placebo and 0.035 mg ethinylestradiol/2 mg cyproterone acetate","journal-title":"Contraception","doi-asserted-by":"crossref"},{"DOI":"10.1053/cjwh.2001.25638","key":"10.1016/j.jaad.2023.12.017_bib136","year":"2001","issue":null,"author":"Maloney JM Arbit","volume":"1","first-page":"123","unstructured":null,"article-title":"Use of low-dose oral contraceptive containing norethindrone acetate and ethinyl estradiol in the treatment of moderate acne vulgaris","journal-title":"Clin J Wom Health","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.contraception.2007.11.003","key":"10.1016/j.jaad.2023.12.017_bib137","year":"2008","issue":null,"author":"Koltun","volume":"77","first-page":"249","unstructured":null,"article-title":"Efficacy and safety of 3 mg drospirenone/20 mcg ethinylestradiol oral contraceptive administered in 24/4 regimen in the treatment of acne vulgaris: a randomized, double-blind, placebo-controlled trial","journal-title":"Contraception","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.contraception.2009.02.016","key":"10.1016/j.jaad.2023.12.017_bib138","year":"2009","issue":null,"author":"Plewig","volume":"80","first-page":"25","unstructured":null,"article-title":"Efficacy of an oral contraceptive containing EE 0.03 mg and CMA 2 mg (Belara) in moderate acne resolution: a randomized, double-blind, placebo-controlled phase III trial","journal-title":"Contraception","doi-asserted-by":"crossref"},{"DOI":"10.1080/13625180008500411","key":"10.1016/j.jaad.2023.12.017_bib139","year":"2000","issue":null,"author":"Katz","volume":"5","first-page":"248","unstructured":null,"article-title":"Effect of a desogestrel-containing oral contraceptive on the skin","journal-title":"Eur J Contracept Reprod Health Care","doi-asserted-by":"crossref"},{"DOI":"10.1111/1346-8138.15559","key":"10.1016/j.jaad.2023.12.017_bib140","year":"2020","issue":null,"author":"Patiyasikunt","volume":"47","first-page":"1411","unstructured":null,"article-title":"Efficacy and tolerability of low-dose spironolactone and topical benzoyl peroxide in adult female acne: a randomized, double-blind, placebo-controlled trial","journal-title":"J Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1111/j.1365-2133.1984.tb04045.x","key":"10.1016/j.jaad.2023.12.017_bib141","year":"1984","issue":null,"author":"Goodfellow","volume":"111","first-page":"209","unstructured":null,"article-title":"Oral spironolactone improves acne vulgaris and reduces sebum excretion","journal-title":"Br J Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1111/j.1365-2133.1986.tb05722.x","key":"10.1016/j.jaad.2023.12.017_bib142","year":"1986","issue":null,"author":"Muhlemann","volume":"115","first-page":"227","unstructured":null,"article-title":"Oral spironolactone: an effective treatment for acne vulgaris in women","journal-title":"Br J Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1001/jamadermatol.2020.5468","key":"10.1016/j.jaad.2023.12.017_bib143","year":"2021","issue":null,"author":"Barbieri","volume":"157","first-page":"296","unstructured":null,"article-title":"Temporal trends and clinician variability in potassium monitoring of healthy young women treated for acne with spironolactone","journal-title":"JAMA Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1159/000471799","key":"10.1016/j.jaad.2023.12.017_bib144","year":"2017","issue":null,"author":"Grandhi","volume":"233","first-page":"141","unstructured":null,"article-title":"Spironolactone for the treatment of acne: a 4-year retrospective study","journal-title":"Dermatology","doi-asserted-by":"crossref"},{"DOI":"10.1001/jamadermatol.2015.34","key":"10.1016/j.jaad.2023.12.017_bib145","year":"2015","issue":null,"author":"Plovanich","volume":"151","first-page":"941","unstructured":null,"article-title":"Low usefulness of potassium monitoring among healthy young women taking spironolactone for acne","journal-title":"JAMA Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1007/s00266-006-0081-0","key":"10.1016/j.jaad.2023.12.017_bib146","year":"2006","issue":null,"author":"Sato","volume":"30","first-page":"689","unstructured":null,"article-title":"Anti-androgenic therapy using oral spironolactone for acne vulgaris in Asians","journal-title":"Aesthetic Plast Surg","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.ijwd.2019.04.024","key":"10.1016/j.jaad.2023.12.017_bib147","year":"2019","issue":null,"author":"Thiede","volume":"5","first-page":"155","unstructured":null,"article-title":"Hyperkalemia in women with acne exposed to oral spironolactone: a retrospective study from the RADAR (Research on Adverse Drug Events and Reports) program","journal-title":"Int J Womens Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.4103/0378-6323.86482","key":"10.1016/j.jaad.2023.12.017_bib148","year":"2011","issue":null,"author":"Agarwal","volume":"77","first-page":"688","unstructured":null,"article-title":"Oral isotretinoin in different dose regimens for acne vulgaris: a randomized comparative trial","journal-title":"Indian J Dermatol Venereol Leprol","doi-asserted-by":"crossref"},{"DOI":"10.1007/s00403-007-0777-2","key":"10.1016/j.jaad.2023.12.017_bib149","year":"2007","issue":null,"author":"Akman","volume":"299","first-page":"467","unstructured":null,"article-title":"Treatment of acne with intermittent and conventional isotretinoin: a randomized, controlled multicenter study","journal-title":"Arch Dermatol Res","doi-asserted-by":"crossref"},{"DOI":"10.1111/j.1365-2133.2010.10152.x","key":"10.1016/j.jaad.2023.12.017_bib150","year":"2011","issue":null,"author":"Lee","volume":"164","first-page":"1369","unstructured":null,"article-title":"Effectiveness of conventional, low-dose and intermittent oral isotretinoin in the treatment of acne: a randomized, controlled comparative study","journal-title":"Br J Dermatol","doi-asserted-by":"crossref"},{"DOI":null,"key":"10.1016/j.jaad.2023.12.017_bib151","year":"2014","issue":null,"author":"Webster","volume":"13","first-page":"665","unstructured":null,"article-title":"Results of a phase III, double-blind, randomized, parallel-group, non-inferiority study evaluating the safety and efficacy of isotretinoin-Lidose in patients with severe recalcitrant nodular acne","journal-title":"J Drugs Dermatol","doi-asserted-by":null},{"DOI":null,"key":"10.1016/j.jaad.2023.12.017_bib152","year":"2016","issue":"1","author":"Tangjaturonrusamee","volume":"98","first-page":"56","unstructured":null,"article-title":"Comparison of pneumatic broadband light plus adapalene gel 0.3% versus adapalene gel 0.3% monotherapy in the treatment of mild to moderate acne","journal-title":"Cutis","doi-asserted-by":null},{"DOI":"10.1016/S0190-9622(96)90443-0","key":"10.1016/j.jaad.2023.12.017_bib153","year":"1996","issue":null,"author":"Shalita","volume":"34","first-page":"482","unstructured":null,"article-title":"A comparison of the efficacy and safety of adapalene gel 0.1% and tretinoin gel 0.025% in the treatment of acne vulgaris: a multicenter trial","journal-title":"J Am Acad Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1016/S0190-9622(98)70141-0","key":"10.1016/j.jaad.2023.12.017_bib154","year":"1998","issue":null,"author":"Lucky","volume":"38","first-page":"S17","unstructured":null,"article-title":"Comparative efficacy and safety of two 0.025% tretinoin gels: results from a multicenter, double-blind, parallel study","journal-title":"J Am Acad Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1080/09546634.2019.1587884","key":"10.1016/j.jaad.2023.12.017_bib155","year":"2020","issue":"2","author":"Harper","volume":"31","first-page":"160","unstructured":null,"article-title":"Novel tretinoin 0.05% lotion for the once-daily treatment of moderate-to-severe acne vulgaris: assessment of safety and tolerability in subgroups","journal-title":"J Dermatol Treat","doi-asserted-by":"crossref"},{"DOI":"10.1046/j.1365-2133.1998.1390s2017.x","key":"10.1016/j.jaad.2023.12.017_bib156","year":"1998","issue":"Suppl 52","author":"Dunlap","volume":"139","first-page":"17","unstructured":null,"article-title":"Adapalene 0.1% gel for the treatment of acne vulgaris: its superiority compared to tretinoin 0.025% cream in skin tolerance and patient preference","journal-title":"Br J Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1067/mjd.2000.108322","key":"10.1016/j.jaad.2023.12.017_bib157","year":"2000","issue":null,"author":"Kakita","volume":"43","first-page":"S51","unstructured":null,"article-title":"Tazarotene versus tretinoin or adapalene in the treatment of acne vulgaris","journal-title":"J Am Acad Dermatol","doi-asserted-by":"crossref"},{"DOI":null,"key":"10.1016/j.jaad.2023.12.017_bib158","year":"2001","issue":null,"author":"Webster","volume":"67","first-page":"4","unstructured":null,"article-title":"Efficacy and tolerability of once-daily tazarotene 0.1% gel versus once-daily tretinoin 0.025% gel in the treatment of facial acne vulgaris: a randomized trial","journal-title":"Cutis","doi-asserted-by":null},{"DOI":"10.1046/j.1365-2133.1998.1390s2034.x","key":"10.1016/j.jaad.2023.12.017_bib159","year":"1998","issue":"Suppl 52","author":"Galvin","volume":"139","first-page":"34","unstructured":null,"article-title":"Comparative tolerance of adapalene 0.1% gel and six different tretinoin formulations","journal-title":"Br J Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1111/j.1365-2133.1971.tb02533.x","key":"10.1016/j.jaad.2023.12.017_bib160","year":"1971","issue":null,"author":"Pedace","volume":"84","first-page":"465","unstructured":null,"article-title":"Topical retinoic acid in acne vulgaris","journal-title":"Br J Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1159/000251602","key":"10.1016/j.jaad.2023.12.017_bib161","year":"1974","issue":null,"author":"Christiansen","volume":"148","first-page":"82","unstructured":null,"article-title":"Topical tretinoin, vitamin A acid (Airol) in acne vulgaris. A controlled clinical trial","journal-title":"Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1016/S0190-9622(97)70056-2","key":"10.1016/j.jaad.2023.12.017_bib162","year":"1997","issue":null,"author":"Cunliffe","volume":"36","first-page":"S126","unstructured":null,"article-title":"Clinical efficacy and safety comparison of adapalene gel and tretinoin gel in the treatment of acne vulgaris: Europe and U.S. multicenter trials","journal-title":"J Am Acad Dermatol","doi-asserted-by":"crossref"},{"DOI":null,"key":"10.1016/j.jaad.2023.12.017_bib163","year":"1976","issue":null,"author":"Krishnan","volume":"216","first-page":"106","unstructured":null,"article-title":"Comparison of two concentrations of tretinoin solution in the topical treatment of acne vulgaris","journal-title":"Practitioner","doi-asserted-by":null},{"DOI":null,"key":"10.1016/j.jaad.2023.12.017_bib164","year":"1978","issue":null,"author":"Cunliffe","volume":"220","first-page":"479","unstructured":null,"article-title":"Benzoyl peroxide in acne","journal-title":"Practitioner","doi-asserted-by":null},{"DOI":"10.1111/j.1600-0560.1974.tb00628.x","key":"10.1016/j.jaad.2023.12.017_bib165","year":"1974","issue":null,"author":"Fulton","volume":"1","first-page":"191","unstructured":null,"article-title":"Studies on the mechanism of action to topical benzoyl peroxide and vitamin A acid in acne vulgaris","journal-title":"J Cutan Pathol","doi-asserted-by":"crossref"},{"DOI":"10.1159/000249352","key":"10.1016/j.jaad.2023.12.017_bib166","year":"1986","issue":null,"author":"Fyrand","volume":"172","first-page":"263","unstructured":null,"article-title":"Water-based versus alcohol-based benzoyl peroxide preparations in the treatment of acne vulgaris","journal-title":"Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1111/j.1365-4362.1986.tb04534.x","key":"10.1016/j.jaad.2023.12.017_bib167","year":"1986","issue":null,"author":"Mills","volume":"25","first-page":"664","unstructured":null,"article-title":"Comparing 2.5%, 5%, and 10% benzoyl peroxide on inflammatory acne vulgaris","journal-title":"Int J Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1080/000155502320323216","key":"10.1016/j.jaad.2023.12.017_bib168","year":"2002","issue":null,"author":"Mills","volume":"82","first-page":"260","unstructured":null,"article-title":"Bacterial resistance and therapeutic outcome following three months of topical acne therapy with 2% erythromycin gel versus its vehicle","journal-title":"Acta Derm Venereol","doi-asserted-by":"crossref"},{"DOI":"10.1001/archdermatol.2009.186","key":"10.1016/j.jaad.2023.12.017_bib169","year":"2009","issue":null,"author":"Dubina","volume":"145","first-page":"1027","unstructured":null,"article-title":"Interaction of topical sulfacetamide and topical dapsone with benzoyl peroxide","journal-title":"Arch Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1001/archderm.1986.01660170113031","key":"10.1016/j.jaad.2023.12.017_bib170","year":"1986","issue":null,"author":"Parry","volume":"122","first-page":"583","unstructured":null,"article-title":"Pseudomembranous colitis caused by topical clindamycin phosphate","journal-title":"Arch Dermatol","doi-asserted-by":"crossref"},{"DOI":null,"key":"10.1016/j.jaad.2023.12.017_bib171","year":"2010","issue":null,"author":"Yentzer","volume":"86","first-page":"103","unstructured":null,"article-title":"Simplifying regimens promotes greater adherence and outcomes with topical acne medications: a randomized controlled trial","journal-title":"Cutis","doi-asserted-by":null},{"DOI":null,"key":"10.1016/j.jaad.2023.12.017_bib172","year":"2019","issue":null,"author":"Rosette","volume":"18","first-page":"412","unstructured":null,"article-title":"Cortexolone 17alpha-propionate (clascoterone) is a novel androgen receptor antagonist that inhibits production of lipids and inflammatory cytokines from sebocytes in vitro","journal-title":"J Drugs Dermatol","doi-asserted-by":null},{"DOI":null,"key":"10.1016/j.jaad.2023.12.017_bib173","year":"2011","issue":null,"author":"Kircik","volume":"10","first-page":"586","unstructured":null,"article-title":"Efficacy and safety of azelaic acid (AzA) gel 15% in the treatment of post-inflammatory hyperpigmentation and acne: a 16-week, baseline-controlled study","journal-title":"J Drugs Dermatol","doi-asserted-by":null},{"DOI":"10.1016/j.jaad.2013.09.010","key":"10.1016/j.jaad.2023.12.017_bib174","year":"2014","issue":null,"author":"Murase","volume":"70","first-page":"401.e1","unstructured":null,"article-title":"Safety of dermatologic medications in pregnancy and lactation: part I. Pregnancy","journal-title":"J Am Acad Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1007/s13555-022-00854-3","key":"10.1016/j.jaad.2023.12.017_bib175","year":"2023","issue":null,"author":"Ly","volume":"13","first-page":"115","unstructured":null,"article-title":"Treatment of acne vulgaris during pregnancy and lactation: a Narrative review","journal-title":"Dermatol Ther","doi-asserted-by":"crossref"},{"DOI":"10.1111/ajd.12075","key":"10.1016/j.jaad.2023.12.017_bib176","year":"2014","issue":null,"author":"Perret","volume":"55","first-page":"111","unstructured":null,"article-title":"Non-antibiotic properties of tetracyclines and their clinical application in dermatology","journal-title":"Australas J Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1001/jamadermatol.2018.4944","key":"10.1016/j.jaad.2023.12.017_bib177","year":"2019","issue":null,"author":"Barbieri","volume":"155","first-page":"290","unstructured":null,"article-title":"Trends in oral antibiotic prescription in dermatology, 2008 to 2016","journal-title":"JAMA Dermatol","doi-asserted-by":"crossref"},{"DOI":null,"key":"10.1016/j.jaad.2023.12.017_bib178","year":"2025","issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":"10.1001/archdermatol.2011.355","key":"10.1016/j.jaad.2023.12.017_bib179","year":"2012","issue":null,"author":"Margolis","volume":"148","first-page":"326","unstructured":null,"article-title":"Association of pharyngitis with oral antibiotic use for the treatment of acne: a cross-sectional and prospective cohort study","journal-title":"Arch Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1056/NEJM197803092981003","key":"10.1016/j.jaad.2023.12.017_bib180","year":"1978","issue":null,"author":"Bartlett","volume":"298","first-page":"531","unstructured":null,"article-title":"Antibiotic-associated pseudomembranous colitis due to toxin-producing clostridia","journal-title":"N Engl J Med","doi-asserted-by":"crossref"},{"DOI":"10.1146/annurev-micro-090110-102824","key":"10.1016/j.jaad.2023.12.017_bib181","year":"2011","issue":null,"author":"Carroll","volume":"65","first-page":"501","unstructured":null,"article-title":"Biology of Clostridium difficile: implications for epidemiology and diagnosis","journal-title":"Annu Rev Microbiol","doi-asserted-by":"crossref"},{"DOI":"10.15585/mmwr.rr6506a1","key":"10.1016/j.jaad.2023.12.017_bib312","year":"2016","issue":"6","author":"Sanchez","volume":"65","first-page":"1","unstructured":null,"article-title":"Core elements of outpatient antibiotic stewardship","journal-title":"MMWR Recomm Rep","doi-asserted-by":"crossref"},{"DOI":"10.1111/jdv.13776","key":"10.1016/j.jaad.2023.12.017_bib182","year":"2016","issue":null,"author":"Nast","volume":"30","first-page":"1261","unstructured":null,"article-title":"European evidence-based (S3) guideline for the treatment of acne - update 2016 - short version","journal-title":"J Eur Acad Dermatol Venereol","doi-asserted-by":"crossref"},{"DOI":null,"key":"10.1016/j.jaad.2023.12.017_bib183","year":"2019","issue":null,"author":"Oon","volume":"12","first-page":"34","unstructured":null,"article-title":"Acne management guidelines by the Dermatological Society of Singapore","journal-title":"J Clin Aesthet Dermatol","doi-asserted-by":null},{"DOI":null,"key":"10.1016/j.jaad.2023.12.017_bib184","year":"2010","issue":null,"author":"Gold","volume":"85","first-page":"94","unstructured":null,"article-title":"Effective and safe combination therapy for severe acne vulgaris: a randomized, vehicle-controlled, double-blind study of adapalene 0.1%-benzoyl peroxide 2.5% fixed-dose combination gel with doxycycline hyclate 100 mg","journal-title":"Cutis","doi-asserted-by":null},{"DOI":"10.1001/archderm.142.5.605","key":"10.1016/j.jaad.2023.12.017_bib185","year":"2006","issue":null,"author":"Leyden","volume":"142","first-page":"605","unstructured":null,"article-title":"Comparison of tazarotene and minocycline maintenance therapies in acne vulgaris: a multicenter, double-blind, randomized, parallel-group study","journal-title":"Arch Dermatol","doi-asserted-by":"crossref"},{"DOI":null,"key":"10.1016/j.jaad.2023.12.017_bib186","year":"2012","issue":null,"author":"Tan","volume":"11","first-page":"174","unstructured":null,"article-title":"Short-term combination therapy and long-term relapse prevention in the treatment of severe acne vulgaris","journal-title":"J Drugs Dermatol","doi-asserted-by":null},{"DOI":"10.1001/archderm.142.5.597","key":"10.1016/j.jaad.2023.12.017_bib187","year":"2006","issue":null,"author":"Thiboutot","volume":"142","first-page":"597","unstructured":null,"article-title":"Adapalene gel, 0.1%, as maintenance therapy for acne vulgaris: a randomized, controlled, investigator-blind follow-up of a recent combination study","journal-title":"Arch Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1111/j.1346-8138.2012.01626.x","key":"10.1016/j.jaad.2023.12.017_bib188","year":"2012","issue":null,"author":"Moon","volume":"39","first-page":"833","unstructured":null,"article-title":"Antibiotic resistance of microbial strains isolated from Korean acne patients","journal-title":"J Dermatol","doi-asserted-by":"crossref"},{"DOI":null,"key":"10.1016/j.jaad.2023.12.017_bib189","year":"2008","issue":null,"author":"Toossi","volume":"7","first-page":"1149","unstructured":null,"article-title":"Subantimicrobial-dose doxycycline in the treatment of moderate facial acne","journal-title":"J Drugs Dermatol","doi-asserted-by":null},{"DOI":"10.1016/S0140-6736(04)17591-0","key":"10.1016/j.jaad.2023.12.017_bib190","year":"2004","issue":null,"author":"Ozolins","volume":"364","first-page":"2188","unstructured":null,"article-title":"Comparison of five antimicrobial regimens for treatment of mild to moderate inflammatory facial acne vulgaris in the community: randomised controlled trial","journal-title":"Lancet","doi-asserted-by":"crossref"},{"DOI":"10.1002/14651858.CD004425.pub5","key":"10.1016/j.jaad.2023.12.017_bib191","year":"2012","issue":null,"author":"Arowojolu","volume":"6","first-page":null,"unstructured":null,"article-title":"Combined oral contraceptive pills for treatment of acne","journal-title":"Cochrane Database Syst Rev","doi-asserted-by":"crossref"},{"DOI":null,"key":"10.1016/j.jaad.2023.12.017_bib192","year":"2012","issue":null,"author":"Arrington","volume":"90","first-page":"83","unstructured":null,"article-title":"Combined oral contraceptives for the treatment of acne: a practical guide","journal-title":"Cutis","doi-asserted-by":null},{"DOI":"10.1111/j.1529-8019.2009.01261.x","key":"10.1016/j.jaad.2023.12.017_bib193","year":"2009","issue":null,"author":"Harper","volume":"22","first-page":"452","unstructured":null,"article-title":"Should dermatologists prescribe hormonal contraceptives for acne?","journal-title":"Dermatol Ther","doi-asserted-by":"crossref"},{"DOI":"10.3109/09513590009167685","key":"10.1016/j.jaad.2023.12.017_bib194","year":"2000","issue":null,"author":"Rabe","volume":"14","first-page":"223","unstructured":null,"article-title":"Inhibition of skin 5 alpha-reductase by oral contraceptive progestins in vitro","journal-title":"Gynecol Endocrinol","doi-asserted-by":"crossref"},{"DOI":"10.1097/AOG.0000000000003880","key":"10.1016/j.jaad.2023.12.017_bib195","year":"2020","issue":null,"author":"Barbieri","volume":"135","first-page":"1306","unstructured":null,"article-title":"Influence of contraception class on incidence and severity of acne vulgaris","journal-title":"Obstet Gynecol","doi-asserted-by":"crossref"},{"DOI":null,"key":"10.1016/j.jaad.2023.12.017_bib196","year":"2016","issue":null,"author":"Lortscher","volume":"15","first-page":"670","unstructured":null,"article-title":"Hormonal contraceptives and acne: a retrospective analysis of 2147 patients","journal-title":"J Drugs Dermatol","doi-asserted-by":null},{"DOI":null,"key":"10.1016/j.jaad.2023.12.017_bib197","year":"2012","issue":null,"author":"Davtyan","volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":"10.2165/11535450-000000000-00000","key":"10.1016/j.jaad.2023.12.017_bib198","year":"2010","issue":null,"author":"Kelly","volume":"30","first-page":"325","unstructured":null,"article-title":"Effects of oral contraceptives containing ethinylestradiol with either drospirenone or levonorgestrel on various parameters associated with well-being in healthy women: a randomized, single-blind, parallel-group, multicentre study","journal-title":"Clin Drug Investig","doi-asserted-by":"crossref"},{"DOI":"10.2340/0001555564517523","key":"10.1016/j.jaad.2023.12.017_bib199","year":"1984","issue":null,"author":"Palatsi","volume":"64","first-page":"517","unstructured":null,"article-title":"Serum total and unbound testosterone and sex hormone binding globulin (SHBG) in female acne patients treated with two different oral contraceptives","journal-title":"Acta Derm Venereol","doi-asserted-by":"crossref"},{"DOI":"10.1067/mob.2003.294","key":"10.1016/j.jaad.2023.12.017_bib200","year":"2003","issue":null,"author":"Rosen","volume":"188","first-page":"1158","unstructured":null,"article-title":"A randomized controlled trial of second- versus third-generation oral contraceptives in the treatment of acne vulgaris","journal-title":"Am J Obstet Gynecol","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.contraception.2003.12.017","key":"10.1016/j.jaad.2023.12.017_bib201","year":"2004","issue":null,"author":"Winkler","volume":"69","first-page":"469","unstructured":null,"article-title":"Cycle control, quality of life and acne with two low-dose oral contraceptives containing 20 microg ethinylestradiol","journal-title":"Contraception","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.contraception.2014.06.002","key":"10.1016/j.jaad.2023.12.017_bib202","year":"2014","issue":null,"author":"Jaisamrarn","volume":"90","first-page":"535","unstructured":null,"article-title":"A comparison of multiphasic oral contraceptives containing norgestimate or desogestrel in acne treatment: a randomized trial","journal-title":"Contraception","doi-asserted-by":"crossref"},{"DOI":null,"key":"10.1016/j.jaad.2023.12.017_bib203","year":"2004","issue":null,"author":"Thorneycroft","volume":"74","first-page":"123","unstructured":null,"article-title":"Superiority of a combined contraceptive containing drospirenone to a triphasic preparation containing norgestimate in acne treatment","journal-title":"Cutis","doi-asserted-by":null},{"DOI":"10.1016/S0010-7824(99)00093-1","key":"10.1016/j.jaad.2023.12.017_bib204","year":"1999","issue":null,"author":"Thorneycroft","volume":"60","first-page":"255","unstructured":null,"article-title":"Effect of low-dose oral contraceptives on androgenic markers and acne","journal-title":"Contraception","doi-asserted-by":"crossref"},{"DOI":"10.1001/jama.285.17.2232","key":"10.1016/j.jaad.2023.12.017_bib205","year":"2001","issue":null,"author":"Stewart","volume":"285","first-page":"2232","unstructured":null,"article-title":"Clinical breast and pelvic examination requirements for hormonal contraception: current practice vs evidence","journal-title":"JAMA","doi-asserted-by":"crossref"},{"DOI":null,"key":"10.1016/j.jaad.2023.12.017_bib206","year":"2016","issue":null,"author":"Curtis","volume":"65","first-page":"1","unstructured":null,"article-title":"U.S. Selected practice recommendations for contraceptive use, 2016","journal-title":"MMWR Recomm Rep","doi-asserted-by":null},{"DOI":null,"key":"10.1016/j.jaad.2023.12.017_bib207","year":"2012","issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":null,"key":"10.1016/j.jaad.2023.12.017_bib208","year":"2016","issue":null,"author":"Curtis","volume":"65","first-page":"1","unstructured":null,"article-title":"U.S. Medical eligibility criteria for contraceptive use, 2016","journal-title":"MMWR Recomm Rep","doi-asserted-by":null},{"DOI":null,"key":"10.1016/j.jaad.2023.12.017_bib209","year":"2011","issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":"10.1016/j.clindermatol.2009.03.006","key":"10.1016/j.jaad.2023.12.017_bib210","year":"2010","issue":null,"author":"Katsambas","volume":"28","first-page":"17","unstructured":null,"article-title":"Hormonal therapy for acne: why not as first line therapy? facts and controversies","journal-title":"Clin Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1158/1055-9965.EPI-13-0298","key":"10.1016/j.jaad.2023.12.017_bib211","year":"2013","issue":null,"author":"Gierisch","volume":"22","first-page":"1931","unstructured":null,"article-title":"Oral contraceptive use and risk of breast, cervical, colorectal, and endometrial cancers: a systematic review","journal-title":"Cancer Epidemiol Biomarkers Prev","doi-asserted-by":"crossref"},{"DOI":"10.1097/AOG.0b013e318291c235","key":"10.1016/j.jaad.2023.12.017_bib212","year":"2013","issue":null,"author":"Havrilesky","volume":"122","first-page":"139","unstructured":null,"article-title":"Oral contraceptive pills as primary prevention for ovarian cancer: a systematic review and meta-analysis","journal-title":"Obstet Gynecol","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.ajog.2017.02.002","key":"10.1016/j.jaad.2023.12.017_bib213","year":"2017","issue":null,"author":"Iversen","volume":"216","first-page":"580.e1","unstructured":null,"article-title":"Lifetime cancer risk and combined oral contraceptives: the Royal College of general practitioners' oral contraception study","journal-title":"Am J Obstet Gynecol","doi-asserted-by":"crossref"},{"DOI":"10.1016/S0140-6736(07)61684-5","key":"10.1016/j.jaad.2023.12.017_bib214","year":"2007","issue":null,"author":"Appleby","volume":"370","first-page":"1609","unstructured":null,"article-title":"Cervical cancer and hormonal contraceptives: collaborative reanalysis of individual data for 16,573 women with cervical cancer and 35,509 women without cervical cancer from 24 epidemiological studies","journal-title":"Lancet","doi-asserted-by":"crossref"},{"DOI":null,"key":"10.1016/j.jaad.2023.12.017_bib215","year":"2016","issue":null,"author":"Roura","volume":"11","first-page":null,"unstructured":null,"article-title":"The influence of hormonal factors on the risk of developing cervical cancer and pre-cancer: results from the EPIC cohort","journal-title":"PLoS One","doi-asserted-by":null},{"DOI":"10.1097/AOG.0b013e3181cb50b5","key":"10.1016/j.jaad.2023.12.017_bib216","year":"2010","issue":null,"author":null,"volume":"115","first-page":"206","unstructured":null,"article-title":"ACOG practice bulletin no. 110: noncontraceptive uses of hormonal contraceptives","journal-title":"Obstet Gynecol","doi-asserted-by":"crossref"},{"DOI":"10.1097/AOG.0000000000004659","key":"10.1016/j.jaad.2023.12.017_bib217","year":"2022","issue":null,"author":null,"volume":"139","first-page":"350","unstructured":null,"article-title":"Patient-centered contraceptive counseling: ACOG Committee statement number 1","journal-title":"Obstet Gynecol","doi-asserted-by":"crossref"},{"DOI":"10.1016/S0190-9622(97)80322-2","key":"10.1016/j.jaad.2023.12.017_bib218","year":"1997","issue":null,"author":"Helms","volume":"36","first-page":"705","unstructured":null,"article-title":"Oral contraceptive failure rates and oral antibiotics","journal-title":"J Am Acad Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1001/archderm.1994.01690030128027","key":"10.1016/j.jaad.2023.12.017_bib219","year":"1994","issue":null,"author":"London","volume":"130","first-page":"392","unstructured":null,"article-title":"Frequency of pregnancy in acne patients taking oral antibiotics and oral contraceptives","journal-title":"Arch Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1097/00006250-200606000-00055","key":"10.1016/j.jaad.2023.12.017_bib220","year":"2006","issue":null,"author":null,"volume":"107","first-page":"1453","unstructured":null,"article-title":"ACOG practice bulletin. No. 73: use of hormonal contraception in women with coexisting medical conditions","journal-title":"Obstet Gynecol","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.jaad.2007.09.024","key":"10.1016/j.jaad.2023.12.017_bib221","year":"2008","issue":null,"author":"Krunic","volume":"58","first-page":"60","unstructured":null,"article-title":"Efficacy and tolerance of acne treatment using both spironolactone and a combined contraceptive containing drospirenone","journal-title":"J Am Acad Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1186/1472-6904-11-23","key":"10.1016/j.jaad.2023.12.017_bib222","year":"2011","issue":null,"author":"Bird","volume":"11","first-page":"23","unstructured":null,"article-title":"The association between drospirenone and hyperkalemia: a comparative-safety study","journal-title":"BMC Clin Pharmacol","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.contraception.2021.05.002","key":"10.1016/j.jaad.2023.12.017_bib223","year":"2021","issue":null,"author":"Creinin","volume":"104","first-page":"222","unstructured":null,"article-title":"Estetrol-drospirenone combination oral contraceptive: North American phase 3 efficacy and safety results","journal-title":"Contraception","doi-asserted-by":"crossref"},{"DOI":"10.1139/o79-131","key":"10.1016/j.jaad.2023.12.017_bib224","year":"1979","issue":null,"author":"Boisselle","volume":"57","first-page":"1042","unstructured":null,"article-title":"Interaction of spironolactone with rat skin androgen receptor","journal-title":"Can J Biochem","doi-asserted-by":"crossref"},{"DOI":"10.1016/0024-3205(74)90330-0","key":"10.1016/j.jaad.2023.12.017_bib225","year":"1974","issue":null,"author":"Menard","volume":"15","first-page":"1639","unstructured":null,"article-title":"Spironolactone and cytochrome P-450: impairment of steroid hydroxylation in the adrenal cortex","journal-title":"Life Sci","doi-asserted-by":"crossref"},{"DOI":"10.1210/endo-94-6-1628","key":"10.1016/j.jaad.2023.12.017_bib226","year":"1974","issue":null,"author":"Menard","volume":"94","first-page":"1628","unstructured":null,"article-title":"Spironolactone and testicular cytochrome P-450: decreased testosterone formation in several species and changes in hepatic drug metabolism","journal-title":"Endocrinology","doi-asserted-by":"crossref"},{"DOI":"10.1210/jcem-46-2-338","key":"10.1016/j.jaad.2023.12.017_bib227","year":"1978","issue":null,"author":"Rifka","volume":"46","first-page":"338","unstructured":null,"article-title":"Interaction of digitalis and spironolactone with human sex steroid receptors","journal-title":"J Clin Endocrinol Metab","doi-asserted-by":"crossref"},{"DOI":"10.1159/000211271","key":"10.1016/j.jaad.2023.12.017_bib228","year":"1994","issue":null,"author":"Zouboulis","volume":"7","first-page":"33","unstructured":null,"article-title":"Androgens affect the activity of human sebocytes in culture in a manner dependent on the localization of the sebaceous glands and their effect is antagonized by spironolactone","journal-title":"Skin Pharmacol","doi-asserted-by":"crossref"},{"DOI":"10.1016/0022-4731(85)90236-5","key":"10.1016/j.jaad.2023.12.017_bib229","year":"1985","issue":null,"author":"Serafini","volume":"23","first-page":"191","unstructured":null,"article-title":"The effect of spironolactone on genital skin 5 alpha-reductase activity","journal-title":"J Steroid Biochem","doi-asserted-by":"crossref"},{"DOI":null,"key":"10.1016/j.jaad.2023.12.017_bib230","year":"2018","issue":null,"author":"Barbieri","volume":"17","first-page":"632","unstructured":null,"article-title":"Frequency of treatment switching for spironolactone compared to oral tetracycline-class antibiotics for women with acne: a retrospective cohort study 2010-2016","journal-title":"J Drugs Dermatol","doi-asserted-by":null},{"DOI":"10.1007/s40257-016-0245-x","key":"10.1016/j.jaad.2023.12.017_bib231","year":"2017","issue":null,"author":"Layton","volume":"18","first-page":"169","unstructured":null,"article-title":"Oral spironolactone for acne vulgaris in adult females: a hybrid systematic review","journal-title":"Am J Clin Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.jaad.2020.12.071","key":"10.1016/j.jaad.2023.12.017_bib232","year":"2021","issue":null,"author":"Garg","volume":"84","first-page":"1348","unstructured":null,"article-title":"Long-term use of spironolactone for acne in women: a case series of 403 patients","journal-title":"J Am Acad Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1177/120347540200600604","key":"10.1016/j.jaad.2023.12.017_bib233","year":"2002","issue":null,"author":"Shaw","volume":"6","first-page":"541","unstructured":null,"article-title":"Long-term safety of spironolactone in acne: results of an 8-year followup study","journal-title":"J Cutan Med Surg","doi-asserted-by":"crossref"},{"DOI":null,"key":"10.1016/j.jaad.2023.12.017_bib234","year":"2023","issue":null,"author":"Santer","volume":"381","first-page":null,"unstructured":null,"article-title":"Effectiveness of spironolactone for women with acne vulgaris (SAFA) in England and Wales: pragmatic, multicentre, phase 3, double blind, randomised controlled trial","journal-title":"BMJ","doi-asserted-by":null},{"DOI":null,"key":"10.1016/j.jaad.2023.12.017_bib235","year":"2013","issue":null,"author":"Zeichner","volume":"12","first-page":"1416","unstructured":null,"article-title":"Evaluating and treating the adult female patient with acne","journal-title":"J Drugs Dermatol","doi-asserted-by":null},{"DOI":"10.1016/j.jaad.2018.10.023","key":"10.1016/j.jaad.2023.12.017_bib236","year":"2019","issue":null,"author":"Liszewski","volume":"80","first-page":"1147","unstructured":null,"article-title":"Lack of evidence for feminization of males exposed to spironolactone in utero: a systematic review","journal-title":"J Am Acad Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1001/jamadermatol.2021.5866","key":"10.1016/j.jaad.2023.12.017_bib237","year":"2022","issue":null,"author":"Bommareddy","volume":"158","first-page":"275","unstructured":null,"article-title":"Association of spironolactone use with risk of cancer: a systematic review and meta-analysis","journal-title":"JAMA Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1001/archderm.1983.01650300034012","key":"10.1016/j.jaad.2023.12.017_bib238","year":"1983","issue":null,"author":"Levine","volume":"119","first-page":"480","unstructured":null,"article-title":"Intralesional corticosteroids in the treatment of nodulocystic acne","journal-title":"Arch Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.jaad.2019.02.067","key":"10.1016/j.jaad.2023.12.017_bib239","year":"2019","issue":null,"author":"Alikhan","volume":"81","first-page":"76","unstructured":null,"article-title":"North American clinical management guidelines for hidradenitis suppurativa: a publication from the United States and Canadian Hidradenitis Suppurativa Foundations: part I: diagnosis, evaluation, and the use of complementary and procedural management","journal-title":"J Am Acad Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1007/s00266-008-9152-8","key":"10.1016/j.jaad.2023.12.017_bib240","year":"2008","issue":null,"author":"Hochman","volume":"32","first-page":"705","unstructured":null,"article-title":"Intralesional triamcinolone acetonide for keloid treatment: a systematic review","journal-title":"Aesthetic Plast Surg","doi-asserted-by":"crossref"},{"DOI":"10.1080/02844310500430003","key":"10.1016/j.jaad.2023.12.017_bib241","year":"2006","issue":null,"author":"Muneuchi","volume":"40","first-page":"111","unstructured":null,"article-title":"Long-term outcome of intralesional injection of triamcinolone acetonide for the treatment of keloid scars in Asian patients","journal-title":"Scand J Plast ReConstr Surg Hand Surg","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.jaad.2016.06.049","key":"10.1016/j.jaad.2023.12.017_bib242","year":"2016","issue":null,"author":"Riis","volume":"75","first-page":"1151","unstructured":null,"article-title":"Intralesional triamcinolone for flares of hidradenitis suppurativa (HS): a case series","journal-title":"J Am Acad Dermatol","doi-asserted-by":"crossref"},{"DOI":null,"key":"10.1016/j.jaad.2023.12.017_bib243","year":"1962","issue":null,"author":"Seif-El-Nasr","volume":"45","first-page":"105","unstructured":null,"article-title":"Granuloma annulare. Report of a case treated successfully by intralesional triamcinolone injection","journal-title":"J Egypt Med Assoc","doi-asserted-by":null},{"DOI":"10.1111/j.1365-2133.1975.tb06481.x","key":"10.1016/j.jaad.2023.12.017_bib244","year":"1975","issue":null,"author":"Sparrow","volume":"93","first-page":"85","unstructured":null,"article-title":"Granuloma annulare and necrobiosis lipoidica treated by jet injector","journal-title":"Br J Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1111/jdv.15233","key":"10.1016/j.jaad.2023.12.017_bib245","year":"2019","issue":null,"author":"Zouboulis","volume":"33","first-page":"19","unstructured":null,"article-title":"Hidradenitis suppurativa/acne inversa: a practical framework for treatment optimization - systematic review and recommendations from the HS ALLIANCE working group","journal-title":"J Eur Acad Dermatol Venereol","doi-asserted-by":"crossref"},{"DOI":"10.2340/00015555-1346","key":"10.1016/j.jaad.2023.12.017_bib246","year":"2012","issue":null,"author":"Kwon","volume":"92","first-page":"241","unstructured":null,"article-title":"Clinical and histological effect of a low glycaemic load diet in treatment of acne vulgaris in Korean patients: a randomized, controlled trial","journal-title":"Acta Derm Venereol","doi-asserted-by":"crossref"},{"DOI":null,"key":"10.1016/j.jaad.2023.12.017_bib247","year":"2020","issue":null,"author":"Gallagher","volume":"13","first-page":"41","unstructured":null,"article-title":"Dermatologist use of intralesional triamcinolone in the treatment of acne","journal-title":"J Clin Aesthet Dermatol","doi-asserted-by":null},{"DOI":"10.1046/j.1365-4362.1998.00443.x","key":"10.1016/j.jaad.2023.12.017_bib248","year":"1998","issue":null,"author":"Jansen","volume":"37","first-page":"254","unstructured":null,"article-title":"Acne fulminans","journal-title":"Int J Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1016/0190-9622(93)70076-6","key":"10.1016/j.jaad.2023.12.017_bib249","year":"1993","issue":null,"author":"Karvonen","volume":"28","first-page":"572","unstructured":null,"article-title":"Acne fulminans: report of clinical findings and treatment of twenty-four patients","journal-title":"J Am Acad Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1080/14740338.2022.2102605","key":"10.1016/j.jaad.2023.12.017_bib250","year":"2022","issue":null,"author":"Villani","volume":"21","first-page":"1027","unstructured":null,"article-title":"Oral isotretinoin for acne: a complete overview","journal-title":"Expert Opin Drug Saf","doi-asserted-by":"crossref"},{"DOI":"10.1016/S0190-9622(82)70063-5","key":"10.1016/j.jaad.2023.12.017_bib251","year":"1982","issue":null,"author":"Peck","volume":"6","first-page":"735","unstructured":null,"article-title":"Isotretinoin versus placebo in the treatment of cystic acne. A randomized double-blind study","journal-title":"J Am Acad Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1016/S0190-9622(80)80074-0","key":"10.1016/j.jaad.2023.12.017_bib252","year":"1980","issue":null,"author":"Farrell","volume":"3","first-page":"602","unstructured":null,"article-title":"The treatment of severe cystic acne with 13-cis-retinoic acid: evaluation of sebum production and the clinical response in a multiple-dose trial","journal-title":"J Am Acad Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1111/j.1365-2133.1982.tb00410.x","key":"10.1016/j.jaad.2023.12.017_bib253","year":"1982","issue":null,"author":"King","volume":"107","first-page":"583","unstructured":null,"article-title":"A double-blind study of the effects of 13-cis-retinoic acid on acne, sebum excretion rate and microbial population","journal-title":"Br J Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1016/S0190-9622(84)80100-0","key":"10.1016/j.jaad.2023.12.017_bib254","year":"1984","issue":null,"author":"Strauss","volume":"10","first-page":"490","unstructured":null,"article-title":"Isotretinoin therapy for acne: results of a multicenter dose-response study","journal-title":"J Am Acad Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1111/jdv.12170","key":"10.1016/j.jaad.2023.12.017_bib255","year":"2014","issue":null,"author":"Rademaker","volume":"28","first-page":"747","unstructured":null,"article-title":"Isotretinoin 5 mg daily for low-grade adult acne vulgaris--a placebo-controlled, randomized double-blind study","journal-title":"J Eur Acad Dermatol Venereol","doi-asserted-by":"crossref"},{"DOI":"10.1503/cmaj.140665","key":"10.1016/j.jaad.2023.12.017_bib256","year":"2016","issue":null,"author":"Asai","volume":"188","first-page":"118","unstructured":null,"article-title":"Management of acne: Canadian clinical practice guideline","journal-title":"CMAJ","doi-asserted-by":"crossref"},{"DOI":"10.1111/jdv.13675","key":"10.1016/j.jaad.2023.12.017_bib257","year":"2016","issue":null,"author":"Gollnick","volume":"30","first-page":"1480","unstructured":null,"article-title":"A consensus-based practical and daily guide for the treatment of acne patients","journal-title":"J Eur Acad Dermatol Venereol","doi-asserted-by":"crossref"},{"DOI":"10.1111/bjd.15843","key":"10.1016/j.jaad.2023.12.017_bib258","year":"2017","issue":null,"author":"Le Cleach","volume":"177","first-page":"908","unstructured":null,"article-title":"Guidelines for the management of acne: recommendations from a French multidisciplinary group","journal-title":"Br J Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.jaad.2017.09.078","key":"10.1016/j.jaad.2023.12.017_bib259","year":"2018","issue":null,"author":"Thiboutot","volume":"78","first-page":"S1","unstructured":null,"article-title":"Practical management of acne for clinicians: an international consensus from the global alliance to improve outcomes in acne","journal-title":"J Am Acad Dermatol","doi-asserted-by":"crossref"},{"DOI":null,"key":"10.1016/j.jaad.2023.12.017_bib260","year":"2019","issue":null,"author":"Gómez-Flores","volume":"56","first-page":"441","unstructured":null,"article-title":"[Second joint position paper: use of isotretinoin in severe acne]","journal-title":"Rev Med Inst Mex Seguro Soc","doi-asserted-by":null},{"DOI":"10.1016/j.abd.2020.09.001","key":"10.1016/j.jaad.2023.12.017_bib261","year":"2020","issue":"Suppl 1","author":"Bagatin","volume":"95","first-page":"19","unstructured":null,"article-title":"Consensus on the use of oral isotretinoin in dermatology - Brazilian Society of Dermatology","journal-title":"An Bras Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1111/dth.15974","key":"10.1016/j.jaad.2023.12.017_bib262","year":"2022","issue":null,"author":"Kassem","volume":"35","first-page":null,"unstructured":null,"article-title":"Evaluation of the efficacy and relapse rates of treatment protocols for moderate acne using isotretinoin based on the global acne grading system: randomized, controlled, comparative study","journal-title":"Dermatol Ther","doi-asserted-by":"crossref"},{"DOI":"10.1111/j.1468-3083.2010.03933.x","key":"10.1016/j.jaad.2023.12.017_bib263","year":"2011","issue":null,"author":"Borghi","volume":"25","first-page":"1094","unstructured":null,"article-title":"Low-cumulative dose isotretinoin treatment in mild-to-moderate acne: efficacy in achieving stable remission","journal-title":"J Eur Acad Dermatol Venereol","doi-asserted-by":"crossref"},{"DOI":"10.1111/j.1468-3083.2006.01784.x","key":"10.1016/j.jaad.2023.12.017_bib264","year":"2006","issue":null,"author":"Kaymak","volume":"20","first-page":"1256","unstructured":null,"article-title":"The effectiveness of intermittent isotretinoin treatment in mild or moderate acne","journal-title":"J Eur Acad Dermatol Venereol","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.jaad.2005.11.1061","key":"10.1016/j.jaad.2023.12.017_bib265","year":"2006","issue":null,"author":"Amichai","volume":"54","first-page":"644","unstructured":null,"article-title":"Low-dose isotretinoin in the treatment of acne vulgaris","journal-title":"J Am Acad Dermatol","doi-asserted-by":"crossref"},{"DOI":null,"key":"10.1016/j.jaad.2023.12.017_bib266","year":"2014","issue":null,"author":"Kızılyel","volume":"94","first-page":"234","unstructured":null,"article-title":"Effects of oral isotretinoin on lipids and liver enzymes in acne patients","journal-title":"Cutis","doi-asserted-by":null},{"DOI":null,"key":"10.1016/j.jaad.2023.12.017_bib267","year":"2006","issue":null,"author":"Ghaffarpour","volume":"5","first-page":"878","unstructured":null,"article-title":"Oral isotretinoin for acne, adjusting treatment according to patient's response","journal-title":"J Drugs Dermatol","doi-asserted-by":null},{"DOI":"10.1590/1516-3180.2018.054405072019","key":"10.1016/j.jaad.2023.12.017_bib268","year":"2019","issue":null,"author":"Evaristo","volume":"137","first-page":"363","unstructured":null,"article-title":"Use of oral isotretinoin to treat acne in the public system: a hospital-based retrospective cohort","journal-title":"Sao Paulo Med J","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.jaad.2019.06.025","key":"10.1016/j.jaad.2023.12.017_bib269","year":"2020","issue":null,"author":"Barbieri","volume":"82","first-page":"72","unstructured":null,"article-title":"The clinical utility of laboratory monitoring during isotretinoin therapy for acne and changes to monitoring practices over time","journal-title":"J Am Acad Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1111/jocd.12268","key":"10.1016/j.jaad.2023.12.017_bib270","year":"2017","issue":null,"author":"Yap","volume":"16","first-page":"348","unstructured":null,"article-title":"Safety and efficacy of fixed-dose 10 mg daily isotretinoin treatment for acne vulgaris in Malaysia","journal-title":"J Cosmet Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1001/jamadermatol.2015.3091","key":"10.1016/j.jaad.2023.12.017_bib271","year":"2016","issue":null,"author":"Lee","volume":"152","first-page":"35","unstructured":null,"article-title":"Laboratory monitoring during isotretinoin therapy for acne: a systematic review and meta-analysis","journal-title":"JAMA Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1001/jamadermatol.2022.2044","key":"10.1016/j.jaad.2023.12.017_bib272","year":"2022","issue":null,"author":"Xia","volume":"158","first-page":"942","unstructured":null,"article-title":"Isotretinoin laboratory monitoring in acne treatment: a Delphi consensus study","journal-title":"JAMA Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1111/bjd.21840","key":"10.1016/j.jaad.2023.12.017_bib273","year":"2022","issue":null,"author":"Affleck","volume":"187","first-page":"857","unstructured":null,"article-title":"Is routine laboratory testing in healthy young patients taking isotretinoin necessary: a critically appraised topic","journal-title":"Br J Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1016/0190-9622(92)70088-W","key":"10.1016/j.jaad.2023.12.017_bib274","year":"1992","issue":null,"author":"Dai","volume":"26","first-page":"599","unstructured":null,"article-title":"Epidemiology of isotretinoin exposure during pregnancy","journal-title":"J Am Acad Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.jaad.2010.09.017","key":"10.1016/j.jaad.2023.12.017_bib275","year":"2011","issue":null,"author":"Shin","volume":"65","first-page":"1117","unstructured":null,"article-title":"The impact of the iPLEDGE program on isotretinoin fetal exposure in an integrated health care system","journal-title":"J Am Acad Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.jaad.2013.08.034","key":"10.1016/j.jaad.2023.12.017_bib276","year":"2014","issue":null,"author":"Collins","volume":"70","first-page":"55","unstructured":null,"article-title":"Compliance with pregnancy prevention measures during isotretinoin therapy","journal-title":"J Am Acad Dermatol","doi-asserted-by":"crossref"},{"DOI":null,"key":"10.1016/j.jaad.2023.12.017_bib277","year":"2017","issue":null,"author":null,"volume":"130","first-page":"e251","unstructured":null,"article-title":"Practice bulletin No. 186: long-acting reversible contraception: implants and intrauterine devices","journal-title":"Obstet Gynecol","doi-asserted-by":null},{"DOI":"10.1038/jid.2012.387","key":"10.1016/j.jaad.2023.12.017_bib278","year":"2013","issue":null,"author":"Alhusayen","volume":"133","first-page":"907","unstructured":null,"article-title":"Isotretinoin use and the risk of inflammatory bowel disease: a population-based cohort study","journal-title":"J Invest Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1038/ajg.2009.417","key":"10.1016/j.jaad.2023.12.017_bib279","year":"2009","issue":null,"author":"Bernstein","volume":"104","first-page":"2774","unstructured":null,"article-title":"Isotretinoin is not associated with inflammatory bowel disease: a population-based case-control study","journal-title":"Am J Gastroenterol","doi-asserted-by":"crossref"},{"DOI":"10.1038/ajg.2010.124","key":"10.1016/j.jaad.2023.12.017_bib280","year":"2010","issue":null,"author":"Crockett","volume":"105","first-page":"1986","unstructured":null,"article-title":"Isotretinoin use and the risk of inflammatory bowel disease: a case-control study","journal-title":"Am J Gastroenterol","doi-asserted-by":"crossref"},{"DOI":"10.1001/jamadermatol.2013.1344","key":"10.1016/j.jaad.2023.12.017_bib281","year":"2013","issue":null,"author":"Etminan","volume":"149","first-page":"216","unstructured":null,"article-title":"Isotretinoin and risk for inflammatory bowel disease: a nested case-control study and meta-analysis of published and unpublished data","journal-title":"JAMA Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1038/ajg.2014.8","key":"10.1016/j.jaad.2023.12.017_bib282","year":"2014","issue":null,"author":"Racine","volume":"109","first-page":"563","unstructured":null,"article-title":"Isotretinoin and risk of inflammatory bowel disease: a French nationwide study","journal-title":"Am J Gastroenterol","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.jaad.2020.07.042","key":"10.1016/j.jaad.2023.12.017_bib283","year":"2021","issue":null,"author":"Wright","volume":"84","first-page":"41","unstructured":null,"article-title":"Risk of new-onset inflammatory bowel disease among patients with acne vulgaris exposed to isotretinoin","journal-title":"J Am Acad Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1001/jamadermatol.2014.1540","key":"10.1016/j.jaad.2023.12.017_bib284","year":"2014","issue":null,"author":"Rashtak","volume":"150","first-page":"1322","unstructured":null,"article-title":"Isotretinoin exposure and risk of inflammatory bowel disease","journal-title":"JAMA Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.sder.2005.04.003","key":"10.1016/j.jaad.2023.12.017_bib285","year":"2005","issue":null,"author":"Marqueling","volume":"24","first-page":"92","unstructured":null,"article-title":"Depression and suicidal behavior in acne patients treated with isotretinoin: a systematic review","journal-title":"Semin Cutan Med Surg","doi-asserted-by":"crossref"},{"DOI":"10.1136/bmj.c5812","key":"10.1016/j.jaad.2023.12.017_bib286","year":"2010","issue":null,"author":"Sundstrom","volume":"341","first-page":null,"unstructured":null,"article-title":"Association of suicide attempts with acne and treatment with isotretinoin: retrospective Swedish cohort study","journal-title":"BMJ","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.jad.2021.09.055","key":"10.1016/j.jaad.2023.12.017_bib287","year":"2022","issue":null,"author":"Chen","volume":"296","first-page":"277","unstructured":null,"article-title":"Risk of psychiatric disorders in patients taking isotretinoin: a nationwide, population-based, cohort study in Taiwan","journal-title":"J Affect Disord","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.jaad.2021.01.107","key":"10.1016/j.jaad.2023.12.017_bib288","year":"2021","issue":null,"author":"Ugonabo","volume":"85","first-page":"878","unstructured":null,"article-title":"Psychiatric disorders and suicidal behavior in patients with acne prescribed oral antibiotics versus isotretinoin: analysis of a large commercial insurance claims database","journal-title":"J Am Acad Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1001/archderm.136.10.1231","key":"10.1016/j.jaad.2023.12.017_bib289","year":"2000","issue":null,"author":"Jick","volume":"136","first-page":"1231","unstructured":null,"article-title":"Isotretinoin use and risk of depression, psychotic symptoms, suicide, and attempted suicide","journal-title":"Arch Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1001/jama.2015.18392","key":"10.1016/j.jaad.2023.12.017_bib290","year":"2016","issue":null,"author":"Siu","volume":"315","first-page":"380","unstructured":null,"article-title":"Screening for depression in adults: US preventive services task force recommendation statement","journal-title":"JAMA","doi-asserted-by":"crossref"},{"DOI":"10.1001/jamadermatol.2020.2330","key":"10.1016/j.jaad.2023.12.017_bib291","year":"2020","issue":null,"author":"Secrest","volume":"156","first-page":"1098","unstructured":null,"article-title":"Quality of life assessed using Skindex-16 scores among patients with acne receiving isotretinoin treatment","journal-title":"JAMA Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1080/09546634.2019.1577545","key":"10.1016/j.jaad.2023.12.017_bib292","year":"2019","issue":null,"author":"Bray","volume":"30","first-page":"796","unstructured":null,"article-title":"Is there an association between isotretinoin therapy and adverse mood changes? A prospective study in a cohort of acne patients","journal-title":"J Dermatolog Treat","doi-asserted-by":"crossref"},{"DOI":"10.1111/bjd.21049","key":"10.1016/j.jaad.2023.12.017_bib293","year":"2022","issue":null,"author":"Paljarvi","volume":"187","first-page":"64","unstructured":null,"article-title":"Isotretinoin and adverse neuropsychiatric outcomes: retrospective cohort study using routine data","journal-title":"Br J Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1001/jama.2022.16946","key":"10.1016/j.jaad.2023.12.017_bib294","year":"2022","issue":null,"author":"Mangione","volume":"328","first-page":"1534","unstructured":null,"article-title":"Screening for depression and suicide risk in children and adolescents: US preventive services task force recommendation statement","journal-title":"JAMA","doi-asserted-by":"crossref"},{"DOI":"10.1001/jama.2022.16936","key":"10.1016/j.jaad.2023.12.017_bib295","year":"2022","issue":null,"author":"Mangione","volume":"328","first-page":"1438","unstructured":null,"article-title":"Screening for anxiety in children and adolescents: US preventive services task force recommendation statement","journal-title":"JAMA","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.jaad.2016.02.1148","key":"10.1016/j.jaad.2023.12.017_bib296","year":"2016","issue":null,"author":"Schrom","volume":"75","first-page":"237","unstructured":null,"article-title":"Depression screening using health questionnaires in patients receiving oral isotretinoin for acne vulgaris","journal-title":"J Am Acad Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1097/DSS.0000000000001166","key":"10.1016/j.jaad.2023.12.017_bib297","year":"2017","issue":null,"author":"Waldman","volume":"43","first-page":"1249","unstructured":null,"article-title":"ASDS guidelines task force: consensus recommendations regarding the safety of lasers, dermabrasion, chemical peels, Energy devices, and skin surgery during and after isotretinoin use","journal-title":"Dermatol Surg","doi-asserted-by":"crossref"},{"DOI":"10.1007/s10103-022-03645-6","key":"10.1016/j.jaad.2023.12.017_bib298","year":"2022","issue":null,"author":"Scopelliti","volume":"37","first-page":"3639","unstructured":null,"article-title":"A novel 1726-nm laser system for safe and effective treatment of acne vulgaris","journal-title":"Lasers Med Sci","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.jaad.2023.05.085","key":"10.1016/j.jaad.2023.12.017_bib299","year":"2023","issue":"4","author":"Alexiades","volume":"89","first-page":"703","unstructured":null,"article-title":"Novel 1726 nm laser demonstrates durable therapeutic outcomes and tolerability for moderate-to-severe acne across skin types","journal-title":"J Am Acad Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.3390/nu2101060","key":"10.1016/j.jaad.2023.12.017_bib300","year":"2010","issue":null,"author":"Reynolds","volume":"2","first-page":"1060","unstructured":null,"article-title":"Effect of the glycemic index of carbohydrates on Acne vulgaris","journal-title":"Nutrients","doi-asserted-by":"crossref"},{"DOI":"10.1093/ajcn/86.1.107","key":"10.1016/j.jaad.2023.12.017_bib301","year":"2007","issue":null,"author":"Smith","volume":"86","first-page":"107","unstructured":null,"article-title":"A low-glycemic-load diet improves symptoms in acne vulgaris patients: a randomized controlled trial","journal-title":"Am J Clin Nutr","doi-asserted-by":"crossref"},{"DOI":"10.4103/ijdvl.IJDVL_109_17","key":"10.1016/j.jaad.2023.12.017_bib302","year":"2019","issue":null,"author":"Pavithra","volume":"85","first-page":"486","unstructured":null,"article-title":"A randomized controlled trial of topical benzoyl peroxide 2.5% gel with a low glycemic load diet versus topical benzoyl peroxide 2.5% gel with a normal diet in acne (grades 1-3)","journal-title":"Indian J Dermatol Venereol Leprol","doi-asserted-by":"crossref"},{"DOI":"10.12788/cutis.0067","key":"10.1016/j.jaad.2023.12.017_bib303","year":"2020","issue":null,"author":"Barbieri","volume":"106","first-page":"E4","unstructured":null,"article-title":"Active comparator trial designs used to promote development of innovative new medications","journal-title":"Cutis","doi-asserted-by":"crossref"},{"DOI":"10.1001/jamadermatol.2021.0356","key":"10.1016/j.jaad.2023.12.017_bib304","year":"2021","issue":null,"author":"Miller","volume":"157","first-page":"597","unstructured":null,"article-title":"Use of active comparator trials for topical medications in dermatology","journal-title":"JAMA Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.jaad.2017.06.004","key":"10.1016/j.jaad.2023.12.017_bib305","year":"2017","issue":null,"author":"Gao","volume":"77","first-page":"971","unstructured":null,"article-title":"Acne, sexual orientation, and mental health among young adults in the United States: a population-based, cross-sectional study","journal-title":"J Am Acad Dermatol","doi-asserted-by":"crossref"},{"DOI":null,"key":"10.1016/j.jaad.2023.12.017_bib306","year":"2022","issue":null,"author":"Pathmarajah","volume":"15","first-page":"43","unstructured":null,"article-title":"Acne vulgaris in skin of color: a systematic review of the effectiveness and tolerability of current treatments","journal-title":"J Clin Aesthet Dermatol","doi-asserted-by":null},{"DOI":"10.1001/jamadermatol.2020.5353","key":"10.1016/j.jaad.2023.12.017_bib307","year":"2021","issue":null,"author":"Braun","volume":"157","first-page":"344","unstructured":null,"article-title":"Moderate-to-severe acne and mental health symptoms in Transmasculine persons who have received testosterone","journal-title":"JAMA Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.jid.2020.05.086","key":"10.1016/j.jaad.2023.12.017_bib308","year":"2021","issue":null,"author":"DeGrazia","volume":"141","first-page":"189","unstructured":null,"article-title":"Eligibility criteria related to hormone therapy in acne clinical trials: a systematic review","journal-title":"J Invest Dermatol","doi-asserted-by":"crossref"},{"DOI":null,"key":"10.1016/j.jaad.2023.12.017_bib309","year":"2022","issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":"10.1016/j.jaad.2018.02.042","key":"10.1016/j.jaad.2023.12.017_bib310","year":"2019","issue":null,"author":"Yeung","volume":"80","first-page":"581","unstructured":null,"article-title":"Dermatologic care for lesbian, gay, bisexual, and transgender persons: terminology, demographics, health disparities, and approaches to care","journal-title":"J Am Acad Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.jaad.2013.09.009","key":"10.1016/j.jaad.2023.12.017_bib311","year":"2014","issue":null,"author":"Butler","volume":"70","first-page":"417.e1","unstructured":null,"article-title":"Safety of dermatologic medications in pregnancy and lactation: part II. Lactation","journal-title":"J Am Acad Dermatol","doi-asserted-by":"crossref"}],"short-title":[],"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,5]]}},"update-policy":"https://doi.org/10.1016/elsevier_cm_policy","alternative-id":["S0190962223033893"],"content-domain":{"domain":["clinicalkey.fr","jaad.org","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"original-title":[],"container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2024,5]]},"reference-count":312,"published-online":null,"references-count":312,"short-container-title":["Journal of the American Academy of Dermatology"],"is-referenced-by-count":189},"unpaywall":{"doi":"10.1016/j.jaad.2023.12.017","is_oa":true,"title":"Guidelines of care for the management of acne vulgaris","updated":"2025-08-17T18:46:03+00:00","published_date":"2024-01-30","best_oa_location":{"url":"http://www.jaad.org/article/S0190962223033893/pdf","pmh_id":null,"url_for_pdf":"http://www.jaad.org/article/S0190962223033893/pdf","url_for_landing_page":"https://doi.org/10.1016/j.jaad.2023.12.017"}}},"created_at":"2025-09-20T08:37:26.392Z","updated_at":"2025-09-20T08:53:46.685Z","tags":[{"paper_doi":"10.1016/j.jaad.2023.12.017","tag_type":"age_group","value":"mixed","value_numeric":null},{"paper_doi":"10.1016/j.jaad.2023.12.017","tag_type":"category","value":"Dermatology","value_numeric":null},{"paper_doi":"10.1016/j.jaad.2023.12.017","tag_type":"condition","value":"Acne Vulgaris","value_numeric":null},{"paper_doi":"10.1016/j.jaad.2023.12.017","tag_type":"generic","value":"azelaic acid","value_numeric":null},{"paper_doi":"10.1016/j.jaad.2023.12.017","tag_type":"generic","value":"clascoterone","value_numeric":null},{"paper_doi":"10.1016/j.jaad.2023.12.017","tag_type":"generic","value":"doxycycline","value_numeric":null},{"paper_doi":"10.1016/j.jaad.2023.12.017","tag_type":"generic","value":"isotretinoin","value_numeric":null},{"paper_doi":"10.1016/j.jaad.2023.12.017","tag_type":"generic","value":"minocycline","value_numeric":null},{"paper_doi":"10.1016/j.jaad.2023.12.017","tag_type":"generic","value":"salicylic acid","value_numeric":null},{"paper_doi":"10.1016/j.jaad.2023.12.017","tag_type":"generic","value":"sarecycline","value_numeric":null},{"paper_doi":"10.1016/j.jaad.2023.12.017","tag_type":"generic","value":"spironolactone","value_numeric":null},{"paper_doi":"10.1016/j.jaad.2023.12.017","tag_type":"modality","value":"Androgen Receptor Inhibitor","value_numeric":null},{"paper_doi":"10.1016/j.jaad.2023.12.017","tag_type":"modality","value":"Hormonal Therapy","value_numeric":null},{"paper_doi":"10.1016/j.jaad.2023.12.017","tag_type":"modality","value":"Intralesional Corticosteroid","value_numeric":null},{"paper_doi":"10.1016/j.jaad.2023.12.017","tag_type":"modality","value":"Oral Retinoid","value_numeric":null},{"paper_doi":"10.1016/j.jaad.2023.12.017","tag_type":"modality","value":"Oral Tetracycline","value_numeric":null},{"paper_doi":"10.1016/j.jaad.2023.12.017","tag_type":"modality","value":"Topical Antibiotic","value_numeric":null},{"paper_doi":"10.1016/j.jaad.2023.12.017","tag_type":"modality","value":"Topical Keratolytic","value_numeric":null},{"paper_doi":"10.1016/j.jaad.2023.12.017","tag_type":"modality","value":"Topical Retinoid","value_numeric":null},{"paper_doi":"10.1016/j.jaad.2023.12.017","tag_type":"study_design","value":"Clinical Practice Guideline","value_numeric":null},{"paper_doi":"10.1016/j.jaad.2023.12.017","tag_type":"warning","value":"Design classification noted as a clinical practice guideline based on a systematic review with GRADE; taxonomy may vary across sources.","value_numeric":null},{"paper_doi":"10.1016/j.jaad.2023.12.017","tag_type":"warning","value":"Only high-level recommendations are available in the provided text; quantitative outcomes and dosing details are not included here.","value_numeric":null}],"summaries":{"what_studied":"An evidence-based clinical guideline for acne vulgaris, developed via systematic review using GRADE, covering management in preadolescents (≥9 years), adolescents, and adults.","key_result":"The guideline issues 18 recommendations and 5 good practice statements: strong recommendations for benzoyl peroxide, topical retinoids, topical antibiotics, and oral doxycycline; strong for oral isotretinoin in severe, scarring/psychosocial burden, or refractory acne; conditional for topical clascoterone, salicylic acid, and azelaic acid, and for oral minocycline, sarecycline, combined oral contraceptives, and spironolactone; good practice to combine topical agents with different mechanisms, limit systemic antibiotic use, pair systemic antibiotics with topicals, and add intralesional corticosteroids for larger lesions.","practice_takeaway":"Use benzoyl peroxide and a topical retinoid (± topical antibiotic) as core therapy; add oral doxycycline when needed, and reserve isotretinoin for severe, scarring/psychosocial burden, or refractory cases. Consider clascoterone, salicylic or azelaic acid, minocycline or sarecycline, combined oral contraceptives, or spironolactone as conditionally recommended options; combine topicals, minimize systemic antibiotic exposure, and use intralesional corticosteroids for large lesions."}}],"initialOffset":2,"fetchConfig":{"kind":"tags","tags":[{"tag_type":"modality","value":"Oral Retinoid"}]},"breadcrumbItems":[{"name":"Home","href":"/"},{"name":"Research Hub","href":"/hub"},{"name":"Modalities","href":"/hub/tag/modality"},{"name":"Oral Retinoid"}],"hrefConfig":{"basePath":"/hub/papers","webViewQueryParams":{"hub_ctx":"tag","hub_tag_type":"modality","hub_tag_value":"Oral Retinoid"}}}]]

Papers